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CHAPTER 1
INTRODUCTION 
Adapted from:
Flavio Forrer, Roelf Valkema, Dik J. Kwekkeboom, Marion de Jong, 
Eric P. Krenning
Best Practice & Research Clinical Endocrinology & Metabolism 
2007;21:111-129
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In targeted radionuclide therapy the goal is to deliver the highest radioactivity possible to the 
target cell while the absorption of the radioactivity in non-target tissue should be as low as 
achievable. Usually, this goal is reached by coupling the radionuclide to a vector which 
recognises a structure, e.g. receptor, on the target cell. By far the most established 
combination is the somatostatin receptor (sst) and radiolabeled somatostatin analogues.  
 
The majority of neuroendocrine tumours feature a strong over-expression of the somatostatin 
receptors (sst), mainly subtype 2 (sst2). Somatostatin receptors are attractive targets for 
radiolabelled peptides since the density of sst on tumours is vastly higher than on non tumour 
tissue [1,2]. In addition to the favourable receptor distribution, sst2 internalises into the cell 
after a ligand bound to the receptor. Consequently, radioactivity delivered by the vector is 
captured in the target cell after binding [3]. 
 
Development of Peptide Receptor Radionuclide Therapy  
Somatostatin receptor scintigraphy was introduced in the late 1980s and after the development 
of [Indium-111-DTPA0]-octreotide ([111In-DTPA0]-octreotide) this radiolabelled hormone 
analogue became the gold standard for staging sst-positive neuroendocrine tumours [4,5]. 
Since then many improvements concerning the peptide and the radiolabelling were made. 
Nowadays, somatostatin analogues labelled with positron emitters are available. The use of 
these compounds with an integrated PET/CT camera provides a highly valuable combination 
of physiological and anatomical information [6-8].  
 
The high tumour to non-tumour ratio that can be achieved with radiolabelled somatostatin 
analogues resulted in attempts to treat patients with metastatic, sst-positive, neuroendocrine 
tumours with these drugs. In turn, diagnostic scans with radiolabelled somatostatin analogues 
are not only used for staging of patients, but also to identify suitable candidates for peptide 
receptor radionuclide therapy (PRRT) and for the monitoring of the therapy.  
 
The first therapy studies using radiolabelled somatostatin analogues were performed with high 
dosages of 111In-octreotide which was available for diagnostic purposes at that time [9-12]. 
Later on peptides with higher receptor affinity were developed and conjugated with the 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator, which allowed 
stable labelling with the pure, high energy beta-emitter Yttrium-90 (90Y). A number of studies 
using [90Y-DOTA0,Tyr3]octreotide (90Y-DOTATOC), [90Y-DOTA]lanreotide and [90Y-
DOTA0,Tyr3]octreotate have been published [13-19]. In a next step, studies using the 
intermediate energy beta emitter Lutetium-177 (177Lu) were presented [20-23]. Currently 
several studies using different radionuclides, peptides and treatment protocols are performed 
in different centres. The detailed results of the various studies are reported below.   
 
 
Radionuclides  
 
Over the past decade, the most frequently used radionuclides in PRRT with somatostatin 
analogues were Indium-111 (111In), Yttrium-90 (90Y), and Lutetium-177 (177Lu). These 
radionuclides have different physical characteristics which will influence the effects of the 
therapy. I.e. different particles are emitted at different energies resulting in various tissue 
penetration ranges. The peptide is conjugated with a chelator which forms a stable complex 
with these three radionuclides. Beside the gamma-radiation, which makes 111In suitable for 
imaging with a gamma-camera, 111In emits Auger electrons. Auger electrons are low energy 
electrons with a short tissue penetration range of 0.02 – 10 μm. The first clinical therapy trials 
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were performed with [111In-DTPA0]-octreotide [9,10,24]. In contrast, 90Y is a pure beta-
emitter. The electrons are emitted with a relatively high energy (Emax = 2.28 MeV) resulting in 
a tissue penetration range of up to 12 mm. Therefore, a pronounced “cross fire effect” is 
found when using 90Y. On the one hand the cross fire effect is beneficial since it allows to 
irradiate tumour cells which are not directly targeted by the radiopharmaceutical. On the other 
hand, the long range of the 90Y beta-particles appears to be less favourable concerning kidney 
toxicity [25]. The third radionuclide used frequently for PRRT, 177Lu, emits intermediate 
energy beta-particles with an Emax =  0.5 MeV resulting in tissue penetration range of up to 2 
mm. In addition, 177Lu has two gamma peaks at 113 and 208 keV which makes it suitable for 
imaging with a gamma camera as well. Imaging can be used for posttherapeutic dosimetry 
[20-23].  
 
Another difference between these radionuclides is their physical half-life. Although the 
influence of the physical half-life is not fully understood yet, it is very likely that it influences 
the therapeutic as well as the secondary effects. For 111In and 90Y it is almost identical with 
2.8 and 2.7 days, respectively, whereas the physical half-life of 177Lu is more than double (6.7 
days).  
 
 
Somatostatin analogues used for PRRT 
 
The two known natural somatostatins consist of 14 or 28 amino acids, respectively. As 
neurotransmitter with endocrine and paracrine functions in vivo and are rapidly degraded by 
peptidases. The serum half life of these peptides in blood is approximately 2 minutes which is 
too short to qualify natural somatostatin as a radiopharmaceutical [26].  
 
The breakthrough in somatostatin receptor imaging and consecutively in therapy was made 
when the octapeptide octreotide was radiolabelled [4]. This small peptide is metabolically 
more stable. It has a plasma half-life of approx. 1.7 hours. Initially the non-radiolabelled 
octreotide was developed to be used as a drug inhibiting the secretion of growth hormone, 
which is one of the physiological actions of somatostatin [27].  
 
Five different subtypes of sst are known (sst1 to sst5). Not all subtypes are equally important 
for PRRT [28]. For neuroendocrine tumours sst2 appears to be the most important subtype 
[29]. Octreotide has a high affinity for sst2, a lower affinity for sst3 and sst5 and no affinity for 
sst1 and sst4 (Table 1) [29-31]. Modifications of octreotide, like the conjugation with a 
chelator can provoke a change in the affinity profile. Remarkably, the same holds true when 
identical conjugated peptides are labelled with different radionuclides [29].  
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Table 1  
 
Affinity profiles (IC 50 ) for human sst1–sst5 receptors of a series of somatostatin analogues 
 
 
Peptide sst1 sst2 sst3 sst4 sst5 
Somatostatin-28 5.2±0.3 (19) 2.7±0.3 (19) 7.7±0.9 (15) 5.6±0.4 (19 4.0±0.3 (19) 
Octreotide >10,000 (5) 2.0±0.7 (5) 187±55 (3) >1,000 (4) 22±6 (5) 
DTPA-octreotide  >10,000 (6) 12±2 (5) 376±84 (5) >1,000 (5) 299±50 (6) 
In-DTPA-octreotide   >10,000 (5) 22±3.6 (5) 182±13 (5) >1,000 (5) 237±52 (5) 
DOTA-TOC  >10,000 (7) 14±2.6 (6) 880±324 (4) >1,000 (6) 393±84 (6) 
Y-DOTA-TOC >10,000 (4) 11±1.7 (6) 389±135 (5) >10,000 (5) 114±29(5) 
DOTA-LAN >10,000 (7) 26±3.4 (6) 771±229 (6) >10,000 (4) 73±12 (6) 
Y-DOTA-LAN >10,000 (3) 23±5 (4) 290±105 (4) >10,000 (4) 16±3.4 (4) 
DOTA-OC  >10,000 (3) 14±3 (4) 27±9 (4) >1,000 (4) 103±39 (3) 
Y-DOTA-OC  >10,000 (5) 20±2 (5) 27±8 (5) >10,000 (4) 57±22 (4) 
Ga-DOTA-TOC  >10,000 (6) 2.5±0.5 (7) 613 ±140 (7) >1,000 (6) 73±21 (6) 
Ga-DOTA-OC  >10,000 (3) 7.3±1.9 (4) 120±45 (4) >1,000 (3) 60±14 (4) 
DTPA-[Tyr3]-octreotate   >10,000 (4) 3.9±1 (4) >10,000 (4) >1,000 (4) >1,000 (4) 
DOTA-[Tyr3]-octreotate  >10,000 (3) 1.5±0.4 (3) >1,000 (3) 453±176 (3) 547±160 (3) 
In-DTPA-[Tyr3]-octreotate  >10,000 (3) 1.3±0.2 (3) >10,000 (3) 433±16 (3) >1,000 (3) 
Y-DOTA-[Tyr3]-octreotate  >10,000 (3) 1.6±0.4 (3) >1,000 (3) 523±239 (3) 187±50 (3) 
Ga-DOTA-[Tyr3]-octreotate  >10,000 (3) 0.2±0.04 (3) >1,000 (3) 300±140 (3) 377±18 (3) 
 
All values are IC 50 ± SEM in nM. The number of experiments is in parentheses. 
Reported after Reubi et al. [31]  
 
The introduction of small changes in amino acids of octreotide created a batch of peptides 
with different affinity profiles for the different receptor subtypes (Table 1) [29]. The peptides 
used most frequently in PRRT are discussed in more detail in the next paragraphs.  
 
 
Clinical studies 
 
A number of Phase I and II therapy studies using different somatostatin analogues, different 
radionuclides, and different treatment protocols have been published to date. The numerous 
variables, including different patient characteristics, make it nearly impossible to compare the 
results of these studies properly. However, it became evident that the kidneys and / or the 
bone marrow are the major dose limiting organs for this treatment.  
 
Studies using [111In-DTPA0]octreotide  
[111In-DTPA0]octreotide, developed initially for diagnosis [4],  was the first radiolabelled 
somatostatin analogue used for PRRT. In several studies, the total cumulative dose ranged 
from 3.1 to 160.0 GBq [9-12]. The number of objective responses according to WHO or 
SWOG criteria was low. Valkema et al. reported the outcome in 50 patients with sst-positive 
tumours, including 26 patients with gastroenteropancreatic (GEP) tumours [8]. All patients 
had documented progressive disease (PD) at the time of inclusion. From the 26 patients with 
GEP tumours, 15 (58%) achieved a stabilisation of their disease (SD) and 2 (8%) achieved a 
minor remission (MR), defined as a reduction of tumour mass between 25% and 50%. These 
17 patients (65%) were considered to have benefited from the therapy.  
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Anthony and colleagues reported a trial including 26 evaluable patients with GEP tumours 
[11]. A partial remission (PR) was found in 2 patients (8%) and 21 patients (81%) achieved 
stabilisation (SD) of their disease. However, this study did not use WHO or SWOG criteria to 
define the outcome. In a smaller study, including 12 patients with GEP tumours, Buscombe et 
al. reported results with a follow up of at least 6 months after the last therapy cycle [12]. In 7 
patients (58%) SD was found, 2 patients (17%) achieved a PR and 3 patients (25%) remained 
progressive despite therapy according to RECIST criteria.  
 
Although the number of objective responses was rather small, these results were encouraging, 
especially when seen in the context of the results that can be achieved with other therapy 
modalities like chemotherapy [32]. Nevertheless it appeared that the anti-tumour effect of 
[111In-DTPA0]octreotide is not ideal for macroscopic tumours. 
 
Experimental data collected in rats, suggested that high doses of [111In-DTPA0]octreotide can 
inhibit the growth of sst 2 positive liver metastases after the injection of tumour cells into the 
portal vein [33]. These results indicated that [111In-DTPA0]octreotide might be particularly 
effective in micro-metastases. However, no clinical studies that confirmed these findings are 
available.  
 
Studies using [90Y-DOTA0,Tyr3]octreotide (90Y-DOTATOC), [90Y-DOTA]lanreotide and 
[90Y-DOTA0,Tyr3]octreotate 
In order to improve the anti-tumour effect, subsequent studies were performed with 90Y 
labelled somatostatin analogues. With the introduction of 90Y the need of a new chelator arose 
since it cannot be bound in a sufficient stable way by DTPA [34]. 90Y as well as 177Lu (see 
below) is a “bone seekers”, i.e. free radionuclides would accumulate in the bone which 
consecutively would lead to a high absorbed dose to the bone marrow. DOTA is the most 
frequently used chelator in PRRT. DOTA has the ability to bind 90Y as well as 177Lu stably 
under various conditions [35]. An overview over the most important PRRT studies using 90Y 
is given in Table 2. 
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Table 2 
 
Peptide receptor radionuclide therapy with 90Y- and 177Lu-labelled somatostatin analogues in 
patients with neuroendocrine tumours.  
 
Authors n PD at time of inclusion 
Response a 
CR PR MR b SD PD CR+PR 
[90Y-DOTA0,Tyr3]octreotide (90Y-DOTATOC) 
Otte et al. 
[13] 16 N/I 0 
1  
(6%) N/I 14 (88%) 
1  
(6%) 
1/16 
(6%) 
Waldherr  
et al. [14] 37 
34/37  
(84%) 
1  
(3%) 
9  
(24%) N/I 23 (62%) 
4  
(11%) 
10/37 
(27%) 
Waldherr  
et al. [15] 37 
37/37  
(100%) 
1  
(3%) 
7  
(19%) N/I 
6  
(70%) 
3  
(8%) 
8/37 
(22%) 
Bodei  
et al. [17] 21 N/I 0 
6  
(29%) N/I 11 (52%) 
4  
(19%) 
6/21 
(29%) 
Valkema  
et al. [41] 54 
41/54 c
(76%) 0 
4  
(7%) 
7  
(13%) 33 (61%) 10 (19%) 
4/54 
(7%) 
[90Y-DOTA]-lanreotide 
Virgolini  
et al. [18] 39 
39/39  
(100%) 0 0 
8  
(20%) 17 (44%) 14 (36%) 
0/39 
(0%) 
[90Y-DOTA0,Tyr3]octreatate 
Baumd  
et al. [19,44] 75 
67/75  
(89%) 0 
28d 
(37%) N/I 
39d 
(52%) 
8d  
(11%) 
28/75d 
(37%) 
[177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) 
Kwekkeboom 
et al. [22] 129 
55/129  
(43%) 
3  
(2%) 32 (25%) 
24  
(19%) 44 (34%) 22 (17%) 
35/131 
(27%)
 
N/I, not indicated.  
a Criteria of tumour response (SWOG / WHO): CR (complete remission), no evidence of 
disease; PR (partial remission), >50%reduction in tumour size; SD (stable disease), ±25% 
reduction or increase in tumour size; PD (progressive disease), >25% increase in tumour size. 
b Modification of SWOG criteria including MR (minor remission), between 25 and 50% 
reduction in tumour size. 
c R. Valkema, personal communication, 2004. 
d Criteria for tumor response are not published in this study 
 
The research group at Basel University reported the first clinical results in 1997 [36]. In this 
study 10 patients with sst-positive tumours were included. Two (20%) achieved a PR after 
treatment with [90Y-DOTA0,Tyr3]octreotide (90Y-DOTATOC). In the following studies 
patients were treated with either 6.0 or 7.4 GBq/m2 90Y-DOTATOC. The objective response 
rates (OR) (defined as CR + PR) were 27% (10 out of 37 patients) and 22% (8 out of 37 
patients) respectively [14,15]. In another study from the same group, including 116 patients, 
who were treated with 6.0 to 7.4 GBq/m2 90Y-DOTATOC an OR of 27% was found [16]. This 
study is reported in chapter 2a.  
 
The research group from the European Cancer Institute in Milan also published several 
studies using 90Y-DOTATOC [17,37-40]. In the most recent study [40] Bodei et al. reported 
the results of 141 patients with various sst-positive tumours. An OR was found in 26 out of 
113 patients with progressive disease before therapy (23%) and in 9 out of 28 patients (32%) 
with stable disease before therapy. However, the results were not subdivided for different 
tumour types. In a study reported in more detail [17], 40 patients with sst- positive tumours 
were included. The patients were treated in 2 cycles with a cumulative doses ranging from 5.9 
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to 11.1 GBq. In the group of patients with GEP tumours the OR rate was 29% (6 out of 21 
patients). Eleven out of 21 patients (52%) achieved a stabilisation of their disease and 4 (19%) 
remained progressive.  
 
The goal of a multicentre phase I study, performed in Rotterdam, Brussels, and Tampa, was to 
determine the maximum tolerated injected activity in a single or in four cycles [41-43]. 
Escalating doses of 90Y-DOTATOC up to 9.3 GBq/m2 as a single injection and up to 14.8 
GBq/m2 in four cycles were administered in 60 patients. Fifty-four patients could be treated 
with their maximum allowed activity. From these patients 4 (7%) achieved a PR, in 7 patients 
(13%) a minor response was found, and 33 (61%) had SD. The median time to progression 
was not reached at 26 months after the last treatment cycle. However, the maximum tolerated 
injected activity could not be determined since, based on 86Y-DOTATOC dosimetry, the dose 
to the red marrow would be too high.  
 
Another 90Y labelled peptide, 90Y-DOTA-lanreotide, was investigated in a European 
multicentre trial (MAURITIUS). In total 39 patients with GEP tumours were treated with a 
cumulative dose ranging from 1.9 to 8.6 GBq [18]. Minor remissions were found in 8 out of 
these 39 patients (20%) and 17 patients had SD (44%).  
 
Recently data have been published of a study using the 90Y labelled [DOTA0,Tyr3]octreotate 
[19,44]. However, the treatment schemes are very inconsistent and the evaluation of benefit is 
not defined. The results reported are an objective response rate (PR) of 37% (28 out of 75) 
and a stabilisation of the disease in 39 out of 75 patients (52%). In the same study the 
intraarterial use of [90Y-DOTA0,Tyr3]octreotate in 5 patients is described. However, no 
detailed results for this application are available and all data have not been confirmed by 
another research group.  
 
The first long term follow up and survival data for 90Y-DOTATOC were published by 
Valkema et al. [45]. In this study 58 patients were treated in a dose escalating study with 1.7 
to 32.8 GBq of 90Y-DOTATOC. The response rates were comparable to other studies using 
90Y labelled somatostatin analogues, but in addition to the encouraging response rates a 
significant longer overall survival (36.7 months) was shown compared to a group treated with 
[111In-DTPA0]octreotide (median survival 12.0 months) [9]. Although the relevant patient 
characteristics did not show significant differences, the patients treated with [111In-
DTPA0]octreotide had a somewhat lower Karnofsky Performance Status, which might have 
slightly influenced the results.     
 
The use of different protocols, peptides and the difficulties in the comparison of the patients 
included makes it virtually impossible to compare the results of these therapy-studies with 90Y 
labelled peptides. Nevertheless, the results with ORs rates up to 37% and the suggested 
prolonged overall survival represent an improvement in therapeutic effectiveness compared to 
the studies with [111In-DTPA0]octreotide.  
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
1a Planar scintigraphic scan of the abdomen 46 hours after the injection of 7.4 GBq 
90Y-DOTATOC and 111 MBq 111In-DOTATOC in a patient with a neuroendocrine 
tumor of the pancreas with liver metastases. The scan was performed after the first 
treatment.     
 
1b Planar scintigraphic scan of the abdomen 46 hours after the injection of 7.4 GBq 
90Y-DOTATOC and 111 MBq 111In-DOTATOC in the same patient shown in figure 
1a. The scan was performed after the second treatment. Scintigraphically a clear 
reduction of the primary tumor and the liver metastases can be seen. 
 
Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2a Pretherapeutic CT-scan of the patient shown in figure 1. Multiple liver metastases can 
be seen. 
 
2b CT-scan 3 month after the second treatment of the same patient. Liver metastases 
are not demonstrated anymore.       
1a 1b 
2b 2a 
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Studies using [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) and [177Lu-
DOTA0,Tyr3]octreotide (177Lu-DOTATOC) 
In 2003 the first results from a study using a 177Lu labelled peptide were published [20]. In 
this study 35 patients with neuroendocrine GEP tumours were treated with escalating dosages 
of [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) up to a final cumulative dose of 22.2 – 
29.6 GBq. The effects of the therapy could be evaluated in 34 patients. Three months after the 
last treatment cycle 1 CR, 12 PR, 14 SD and 7 PD (including 3 patients who died during 
therapy) were found. This equals an objective response rate, i.e. PR or CR, of 38%. A later 
update of this study in 76 patients essentially confirmed these results [21]. In the follow-up 
the median time to progression in the patients that had at least SD after the treatment was not 
reached at 25 months from the beginning of the therapy. In a more recent evaluation of 131 
GEP tumour patients these outcomes were confirmed again and a median time to progression 
of more than 36 months was found [22]. The latest evaluation of these patients with focus on 
long term outcome revealed an overall survival which appears to be even longer than the 
results published for 90Y-DOTATOC (D.J. Kwekkeboom, personal communication 2006). 
However, influences resulting from different patient characteristics can currently not be ruled 
out.  
 
So far only one study was published using 177Lu-DOTATOC [23]. One of the inclusion 
criteria was relapse after 90Y-DOTATOC treatment and only one therapy cycle was 
administrated because of the pretreatment. Yet effectiveness of the treatment could be 
demonstrated, but because of the different setting the results of the outcome can not be 
compared. The detailed results are shown in chapter 2b.   
 
 
Side Effects and Toxicity 
 
Generally PRRT can be regarded as a relatively safe treatment and severe side effects are rare, 
especially when compared with side effects in studies using chemotherapy [46-48]. The side 
effects in PRRT can be divided into acute side-effects and more delayed effects caused by 
radiation toxicity. 
 
The acute effects occurring at the time of injection up to a few days after therapy include 
nausea, vomiting and increased pain at tumour sites (approximately 30% of the patients), 
symptoms that were reported after treatments with all radionuclides [5,11,14]. These side 
effects are generally mild, can be controlled by symptomatic treatment. In patients treated 
with 177Lu-DOTATATE mild hair loss was reported [5], however hair growth had normalised 
at follow up 3 to 6 months after the treatment.  
 
Beside these minor side effects severe toxicity may occur as a result of the radiation absorbed 
dose in healthy organs. The organs at risk are mainly the kidneys, the bone marrow and to a 
lower extend the liver.  
 
Haematological toxicity 
Essentially all studies investigating PRRT report haematological toxicity. It appears that the 
absorbed radiation dose to the bone marrow is mainly caused by the circulation of the 
radioactivity in the blood [49], which limits the options to reduce the absorbed dose. Severe 
haematological toxicity (> grade 2 for haemoglobin, white blood cells and platelets) was 
reported in a maximum of 15% of the patients treated [11,13,14,17,21,41]. In general the 
decrease in blood counts was transient. Blood transfusions were needed only occasionally and 
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patients recovered fully. More serious side effects were reported from a study where 3 out of 
50 patients developed a myelodysplastic syndrome (MDS) after treatment with total 
cumulative doses higher than 100 GBq 111In-octreotide [9]. In a dose escalating phase I study 
with 90Y-DOTATOC to determine the maximum tolerated dose (MTD), one patient 
developed a MDS two years after PRRT [41]. In a recently updated record of roughly 500 
patients treated with [177Lu-DOTA0,Tyr3]octreotate, 3 patients developed a MDS (D.J. 
Kwekkeboom, personal communication) and a recent update of roughly 700 patients treated 
with 90Y-DOTATOC showed that 2 patients developed a MDS (J. Mueller-Brand, personal 
communication). Two out of these 5 cases (one in each group) were most probable related to 
prior chemotherapy. Generally, the definition of the cause for these MDS cases is difficult 
because most of the patents that were included into PRRT trials are pretreated, many of them 
with chemotherapy and external beam radiation. Currently a maximum absorbed radiation 
dose to the bone marrow of 2Gy is assumed to be safe [20]. However, most studies lack long 
term follow up data which makes them ineffective to estimate long term risks.  
 
Haematological toxicity following PRRT is frequent but generally mild and transient. MDS 
may occur, but the limited data on long term follow up does not allow a reliable, precise 
estimation of the risk to date. 
 
Renal Toxicity 
Conjugated peptides are predominantly cleared by the kidneys. Although the major part of the 
radiopharmaceutical is excreted into the urine, partial reabsorption in the tubular cells can 
lead to a considerable radiation dose to the kidneys [25,49,50]. It was shown recently that the 
localization of the radiopeptide in the kidney is not homogeneous, but predominantly in the 
cortex where it follows a striped pattern, with most of the radioactivity centred in the inner 
cortical zone [51]. This pattern of up-take results in different dose distributions for different 
radionuclides [25]. The reabsorption of radiolablled somatostatin is mediated by the 
multiligand scavenger receptor megalin [52]. The high capacity of megalin challenges the 
reduction or blockade of renal reabsorption of the radiolabelled somatostatin analogues. 
However, it was proven that the co-administration of amino acids, especially arginine and 
lysine, significantly reduces the renal uptake of radiopeptides [53,54].  
 
Gelatine based plasma expander were recently shown to reduce renal uptake of diagnostic 
[111In-DTPA0]octreotide efficiently in animals and patients [55,56]. However, the benefit in 
patients during PRRT remains to be proven. Another promising approach might be the use of 
amifostine [57,58]. Amifostine is the first drug investigated for PRRT that does not aim at 
reducing the renal uptake but which acts as a radical scavenger to reduce systemically the 
toxic effects of the radiation on normal tissue. Because amifostine is acting by a different 
mechanism, a combination with drugs that reduce the renal uptake appears most promising. 
Combinations of different drugs to reduce renal uptake are worth being tested as well. 
Preliminary results of a combination of gelatine based plasma expander and amino acids 
showed very promising results in rats (unpublished data).  
 
In a phase I study to define the MTD of 90Y-DOTATOC that was performed without amino 
acids co-administration 2 out of 16 patients developed renal toxicity grade IV [13]. Renal 
biopsies of patients treated with 90Y-DOTATOC that developed renal toxicity revealed mainly 
thrombotic microangiopathy and abnormalities in the tubules, histological changes 
comparable to the changes that occur after external beam radiation [59].  Despite the co-
administration of amino acids a number of later studies using 90Y-labelled peptides reported 
renal toxicity [60-63]. The MTD with amino acid co-infusion for 90Y-DOTATOC was defined 
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as 7.4 GBq/m2 body surface in this study. Nevertheless a case of late onset renal toxicity after 
less than 7.4 GBq/m2 was reported [60]. It was shown that individual dosimetry can be helpful 
to avoid kidney failure [62]. An absorbed dose of 23 Gy to the whole kidney is generally 
accepted to be safe. However, this value is derived from external beam radiation (fractions of 
2 Gy) [64] and is therefore not indisputable. In contrast to external beam radiation the 
physical characteristics of the radiation in PRRT is different, applying radiation in a very low 
dose rate over a long period of several days.  
 
In contrast to the use of 90Y labelled somatostatin analogues, no renal toxicity was reported 
after the therapeutic use of very high doses of [111In-DTPA0]octreotide [9]. For 177Lu-
DOTATATE one patient out of a group of 201 patients was reported who developed renal 
insufficiency [21].  
 
This is an indication that the physical characteristics of the radionuclide have a significant 
impact on renal toxicity. While the Auger electrons emitted by 111In have a range of 
approximately 5 μm in tissue, the maximum range of the 90Y electrons can be up to 12 mm. 
Auger electrons emitted within the tubular cells do not reach the radiosensitive glomeruli 
[65]. Several studies investigated kidney toxicity after PRRT more detailed [62,65,66]. It was 
shown that together with the total absorbed dose to the kidney, the dose volume, fractionation 
rate and clinical parameters like hypertension, diabetes and age play an important role for the 
development of kidney failure. Especially the fractionation influences the specific biologic 
efficacy of internally deposited radiation strongly [66].  
If renal toxicity occurs it can not be regarded as fixed kidney damage. It appears rather that 
the loss of function is a continuous process with a defined pace of progression that can be 
expressed as loss of clearance per year [65].  
 
Liver Toxicity  
Beside the fact that most patients who are treated with PRRT suffer from liver metastases, 
physiological uptake in normal liver tissue also occurs after administration of radiolabelled 
somatostatin analogues. The sum of this physiological uptake and the dose to the normal liver 
from the specific uptake in liver metastases can result in a considerable radiation absorbed 
dose to the liver [49]. However, since the tumour load in the liver shows a high interpatient 
variability, it is difficult to generalise radiation absorbed doses to the liver.  
 
In a study using [111In-DTPA0]octreotide three out of 27 patients showed a temporary increase 
in liver enzymes corresponding to a grade 3 liver toxicity (WHO) [11]. All three patients had 
a liver tissue replacement of more than 75% of their hepatic parenchyma by metastases and 
treatment associated necrosis on the computed tomography scans was suggested.  
 
A significant increase in liver enzymes after the administration of 90Y-DOTATOC was 
reported in two studies [41,67]. Valkema et al. reported one transient grade 3 toxicity in a 
group of 60 patients treated with 90Y-DOTATOC in a phase I study [41]. In another study, 15 
patients with known liver metastases (of whom 12 had extensive liver involvement, defined as 
25% or more) from neuroendocrine tumours were treated with three cycles of 120 mCi (4.4 
GBq) each [67]. In four of these 15 patients, one or more of the three liver enzymes that were 
measured (serum aspartate aminotransferase, alanine aminotransferase and alkaline 
phosphatase) increased. Increase was defined as at least one grade, according to the WHO 
criteria, from baseline to final follow-up measurement (4-6 weeks post cycle 3). It was 
concluded that patients with diffuse sst-positive hepatic metastases could be treated with a 
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cumulative administered activity of 360 mCi (13.2 GBq) of 90Y-DOTATOC with only a small 
chance of developing mild acute or subacute hepatic injury. 
 
In the group of patients treated with 177Lu-DOTATATE, significantly increased liver function 
parameters (grade 4 liver toxicity) was evident in two patients after the first cycle of treatment 
(D.J. Kwekkeboom, personal communication, 2004).  
 
In summary, liver toxicity is very rare and if it occurs it is mostly mild and reversible. 
However, extensive liver metastases seem to be a risk factor for liver impairment after PRRT. 
Especially in these patients though, it is difficult to distinguish between real toxicity caused 
by radiation from effects by the metastases themselves.  
 
 
Dosimetry 
 
In order to improve the efficacy of PRRT and to limit toxicity, appropriate dosimetry helps to 
choose an injected activity that delivers an optimal radiation absorbed dose to the tumor while 
the dose to normal organs does not exceed defined limits. Additionally, dosimetry is 
mandatory to characterize a new compound properly in patients, especially when it is foreseen 
for therapy. The basic principles of dosimtery in Nuclear Medicine are explained in chapter 
3a on the basis of a comparison in patients of the two most frequently used peptides for PRRT 
(DOTA-TOC and DOTAT-[Tyr3]-octreotate.  
 
The dose limiting organs in PRRT are usually the kidneys and / or the bone marrow. 
Especially dosimetry of the bone marrow is very challenging since the bone marrow is not a 
solid organ. The definition of the volume and mass is associated with many sources of error. 
For radiolabeled somatostatin analogues, there are several models which are used to calculate 
the absorbed radiation dose to the bone marrow. Most often the residence time of the 
radiopharmaceutical in the bone marrow - a value that is mandatory for dosimetry - is 
calculated from the residence time in the blood. A correction factor is added depending on the 
vector used for treatment [49]. This method was validated by bone marrow aspirations for 
antibodies but not for radiopeptides [68,69].  
 
Reliable dose estimation for the bone marrow is mandatory for several reasons. In order to 
achieve a maximum anti-tumor effect, patients should be treated with the highest justifiable 
dose of the radiopharmaceutical that does not cause serious toxicity. Many studies with 
radiolabeled somatostatin analogues showed that the toxicity is generally mild and transient 
[13,15,20,22]. It should however not be neglected that in a phase 1 study with [111In-
DTPA0]octreotide 3 out of 50 patient developed a myelodysplastic syndrome (MDS) which 
was probably related to the therapy [9]. Calculations from these data resulted in an estimated 
radiation absorbed dose for the bone marrow of approximately 3 Gy. In another study with 
[177Lu-DOTA0,Tyr3]octreotate, one MDS was observed in a patient who had had 
chemotherapy with alkylating agents 2 years before study entry [21]. In the latest update of 
our own records of roughly 500 patients treated with [177Lu-DOTA0,Tyr3]octreotate, 3 
patients (including the patient mentioned before) developed a MDS (unpublished data). To 
avoid MDS, a maximum absorbed dose of 2 Gy to the bone marrow is generally accepted 
[20]. Nevertheless even if this limit is not exceeded the risk for the patient to develop a MDS 
can not be excluded completely, but an accurate estimation of the absorbed dose to the bone 
marrow will help to find an adequate dosage.  
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For daily practise the method to estimate the absorbed dose to the bone marrow has to be 
easily applicable and should not cause a lot of discomfort to the patient. This is given with the 
method to calculate the residence time in the bone marrow from the blood. However, taking a 
bone marrow sample is probably the most reliable method for bone marrow dosimetry. A 
detailed comparison of different methods to calculate the absorbed radiation dose to the bone 
marrow compared with a bone marrow aspiration is made in chapter 3b.     
 
 
Current Clinical Practice 
 
In symptomatic patients at the time of diagnosis metastatic disease is present in 90% and 
surgical cure is not possible [70]. nevertheless it remains an important cornerstone in the 
management of these tumours.  Beside surgery, radiofrequency ablation (RFA) or chemo-
embolisation is a minimal invasive treatment option when the disease is limited to the liver or 
when the tumour load in the liver is very high. Several small series have shown good 
responses [71-73]. However, RFA and chemo-embolisation are not systemic approaches and 
will not treat extrahepatic (occult) disease.  
 
In patients with metastasised neuroendocrine tumours in whom surgery is no longer an option, 
PRRT appears to be the most effective therapeutic option with limited side-effects. 
Conventional chemotherapy and external radiotherapy either alone or in a variety of 
permutations are of minimal efficacy and should be balanced against the decrease in quality 
of life often caused by such agents [73]. Non-radiolabelled somatostatin analogues, 
particularly in a subcutaneous depot formulation are effective in symptom alleviation and 
improvement of quality of life but their effect on tumour burden is very limited [73]. A 
randomised controlled study of PRRT with other treatment modalities is lacking though. The 
‘wait-and-see’ approach often still remains the mainstay of initial management in patients 
with unresectable disease. The rationale for this approach is found in the natural course of 
well-differentiated GEP tumours. Tumours can be indolent for many years and the well-being 
of patients, even with metastasised tumours, can be unchanged for a long period. However, 
the reported studies on PRRT clearly indicate that patients with documented progressive 
disease or a substantial increase in symptoms benefit in a high percentage from this therapy. 
The recognition of the possible benefit of PRRT for patients with GEP tumours is increasing, 
but its implementation within the whole therapeutic array is rather poor. The fact that PRRT is 
a relatively new therapeutic modality may be one of the contributing factors. Another factor is 
the lack of approved radiopharmaceuticals. Several reasons account for this: beside increased 
governmental demands, and therapy-related costs, it has to be kept in mind that 
neuroendocrine tumours are rather rare which limits the interest of the pharmaceutical 
industry to invest specifically into these tumours.   
 
Indications for Peptide Receptor Radionuclide Therapy  
The approach of PRRT with radiolabelled somatostain analogues allows theoretically treating 
all sst-positive tumours. However, due to the potential morbidity of PRRT patients should be 
selected carefully. Incurability by surgery is an absolute prerequisite for the inclusion of a 
patient. In addition, the presence of a sufficient high density of sst has to be proven by means 
of scintigraphy. Usually this will be an 111In-octreotide scintigraphy with sufficient tumour 
uptake. Recently PET with radiolabelled somatostatin analogues became available and might 
be used alternatively However, these PET methods are available only at a few centres, the 
radiopharmaceuticals are not FDA approved yet and the methods have yet to be formally 
validated. Inclusion criteria for most studies were tumour uptake equal or higher than liver 
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uptake on the 111In-octreotide scintigraphy [74]. High uptake on 111In-octreotide scintigraphy 
has been shown to correlate with tumour regression after PRRT [20]. 
 
Because of the potential, renal and haematological toxicity of PRRT patients need to fulfil 
certain minimal criteria in addition. Blood and kidney function parameters have to be checked 
before therapy. Details are given in table 3. Bone metastases, present only in a minority of the 
patients, are not an exclusion criteria. However it seems that bone and cystic lesions respond 
in a more protracted way than the common solid liver metastases although no formal analysis 
to this end are available.  
 
Table 3 
 
Criteria for peptide receptor radionuclide therapy in patients with neuroendocrine tumours 
 
Inclusion 
 
Sufficient tumour uptake on 111In-octreotide scintigrams 
(tumour uptake ≥ liver uptake) 
 
Haematology:  
• Haemoglobin ≥ 5.0 mmol/l 
• White blood cell count ≥ 2–3.5×109/l 
• Platelet count ≥ 75–100×109/l 
 
Kidney function: 
• Creatinin (serum) ≤150 μmol/l or creatinine clearance ≥ 40 ml/min 
 
Karnofsky Performance Status ≥ 50 
 
Life expectancy > 3 months 
 
Written informed consent 
 
Exclusion 
 
Chemotherapy within 6 weeks prior to the start of treatment 
 
Pregnancy/lactation 
 
Distinct restricted liver function 
 
 
 
 
Timing of Therapy  
 
The best time point to initiate PRRT in patients with malignant neuroendocrine tumours 
remains uncertain up to now. The stage of disease at the time of diagnosis is highly variable. 
It ranges from a small localised primary tumour to advanced or even end-stage disease with 
limited liver function and ascites. In addition, the variation in tumour-differentiation results in 
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highly variable rates of progression. In a study in which the relationship between delay of 
diagnosis, extent of disease and survival in 115 patients with carcinoid was studied, a mean 
delay in the diagnosis of 66 months was found [75]. It was concluded that the diagnosis of 
carcinoid is difficult, and therefore a delay of diagnosis by physicians is common. Strikingly, 
the delay of the diagnosis did not correlate with the extent of the disease. However, the extent 
of the disease did correlate with survival. Patients with primary tumours and lymph node 
metastases were less likely to die of carcinoid disease than patients with hepatic metastases, 
carcinomatosis or extra-abdominal metastases. 
Although there are no guidelines yet for the initiation of PRRT there are certain hints that the 
treatment is more effective when given in an earlier stage. The degree of liver involvement is 
inversely related to the chance of remission [22]. In a trial with [111In-DTPA0]octreotide it 
was reported that a beneficial effect of PRRT is less likely in end-stage patients than in 
patients with less tumour burden and in better general conditions [9,45]. Furthermore, it was 
clearly shown that patients benefit in quality of life after PRRT [15,76]. This justifies treating 
all symptomatic patients that fulfil the inclusion criteria and are not responding to treatment 
with non-radiolabelled somatostatin analogues (anymore).  
 
Another argument for an earlier treatment is the fact that neuroendocrine tumour can 
dedifferentiate over time. Dedifferentiation is commonly associated with a decrease in sst 
density. In turn PRRT using radiolabelled somatostatin analogues will be less effective or 
even impossible. The administration of PRRT in an early stage does not exclude patients from 
a later repetition of the treatment. It was shown recently that patients can be retreated. A good 
response after the first treatment cycles was found to be a positive predictor for the 
effectiveness of the retreatment [23]. 
 
A randomised study comparing the long term survival of patients with malignant, 
unresectable neuroendocrine tumours that undergo PRRT compared to a “wait and see” 
strategy is lacking. Keeping in mind the latest follow up data of patients treated with 177Lu-
DOTATATE (median time to progression > 36 months) [20] makes however such a study 
disputable from an ethical point of view.  
 
 
Future Developments 
 
Future research to improve PRRT with radiolabelled somatostatin analogues consists of 5 
main directions. Improving the vehicle, i.e. the peptide, is highly interesting. Many new 
somatostatin analogues with a higher affinity for sst2 or with a wider affinity for several sst 
subtypes were already introduced into the preclinic [77].  
 
Simultaneously investigations have been made to improve the delivery of the 
radiopharmaceutical to the target. This includes the way of application, e.g. intra-arterially, at 
a slower rate or fractionated, as well as the improvement of the availability of the target by 
different peptide concentrations or by modulation of the receptor with drugs [78,79].  
 
Furthermore the most suitable radionuclide will have to be defined. In preclinical studies, 
comparing 90Y and 177Lu it appeared that 90Y was more effective for bigger tumours while 
with 177Lu less relapses occurred when treating smaller lesions [42,80]. Beside the effects on 
the tumour, the different physical properties cause differences in microdosimetry which in 
turn will influence the toxicity profile of a compound [25]. Beside the commonly used 90Y 
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and 177Lu a number of other radionuclides with different physical characteristics including 
alfa-emitters are under investigation [81,82].  
 
In external beam radiation the application of radio-sensitizers to improve the anti-tumour 
effect of the radiation is established [83]. In PRRT, the introduction of combination therapies 
will open a whole new field of research to improve the treatment. A multi-centre trial with 
177Lu-DOTATATE and Capecitabine was initiated recently (E.P. Krenning, personal 
communication, 2006). 
  
Finally, the improvement of the toxicity-profile of the current radiopeptides is an important 
issue. Especially with respect to the reduction of the kidney uptake, several studies were 
recently published and also other strategies to reduce radiation toxicity in general are under 
investigation [55-58]. An important step towards an improved toxicity profile will be a better 
understanding of the low dose rate irradiation. Currently, the generally accepted maximum 
tolerated absorbed doses to normal organs are still derived from external beam radiation [64]. 
There is emerging evidence in the literature of a low dose hypersensitivity phenomenon where 
at low doses and at very low dose rates, a significantly increased cell kill is found compared 
with high dose rates and compared with what would be predicted from the classical linear 
quadratic model [84,85].  
 
 
Other Peptides for new Peptide Receptor Radionuclide Therapies 
 
Beside radiolabelled somatostatin analogues a number of newly developed peptides were 
introduced lately, targeting different receptors [86]. Bombesin is just one example of these 
new peptides. Bombesin is a well characterized 14 amino acid neuropeptide binding (among 
others) to the gastrin-releasing-peptide (GRP) receptor. Several bombesin derivatives with 
high affinity for the GRP receptor have been developed, analogous to somatostatin, labelled 
with an array of radionuclides [87]. Overexpression of GRP receptors was found on many 
neoplasms, especially on prostate and breast cancer. Remarkably the GRP receptor is not 
expressed on healthy prostate tissue. This might give the chance to distinguish in vivo 
between benign and malignant prostate nodules by means of receptor imaging and in a second 
step to apply PRRT to GRP receptor-positive tumours.  
 
Gastrin analogues have a high affinity for the Cholecystokinin (CCK) B-receptor which is 
overexpressed e.g. on medullary thyroid carcinomas. To date eight patients with advanced 
metastatic disease were injected in a dose-escalation study with potentially therapeutic 
activities of a 90Y-labelled minigastrin derivative at 4-6-weekly intervals with 1.1-1.8 GBq/m2 
per injection for a maximum of four injections. Hematologic and renal were identified as the 
dose-limiting toxicities. Two patients experienced partial remissions, 4 stabilization of their 
previously rapidly progressing disease [88].  
 
Clinical Summary  
 
PRRT has been proven to be an effective and safe treatment alternative for sst-positive, 
unresectable neuroendocrine tumours. Currently the maximum tolerated dose is defined by 
the dose to the critical organs, kidney and bone marrow. It is likely that the dose can be 
increased in future by the introduction of new protective agents, different treatment schemes 
and radionuclides.  
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The present data in the literature do not allow defining the most suitable peptide and 
radionuclide for the treatment of neuroendocrine tumours. Especially concerning the 
radionuclide there is emerging evidence that a combination of nuclides with different physical 
characteristics might be more effective.  
 
The principle of targeted treatment has a number of obvious advantages over unspecific 
systemic treatments. Therefore PRRT holds great promise for the future.  
 
 
Preclinical Studies 
 
As mentioned previously, new approaches could potentially improve PRRT further but a 
number of questions still need to be answered.  
 
Although results from preclinical studies can not always be translated easily to the clinics, 
preclinical evaluation and test of new compounds or new strategies will remain a corner stone 
to improve PRRT. Before new drugs or treatment strategies are evaluated in patients, they are 
usually tested first in preclinical studies. Animal experiments are of high relevance in this 
stage of the development. To date mainly biodistribution studies were performed. This is 
associated with a large number of animals that are needed to investigate different processes 
and function at different time points.  
 
Over the last years dedicated small animal imaging devices gained increasing influence on 
preclinical research. Particularly single photon emission computed tomography (SPECT) and 
positron emission tomography (PET) as tools for molecular imaging were proven to be 
valuable e.g. to follow physiological processes in an animal over time.  
 
Small animal SPECT/CT 
For our research we had a dedicated small animal SPECT/CT at our disposal [89]. The 
camera was a four headed multiplexing multi-pinhole camera. Each head is fitted with an 
application-specific tungsten collimator with nine pinholes. The rat apertures, e.g., comprise a 
total of 36 2-mm-diameter pinholes imaging a cylindrical field of view that is 60 mm in 
diameter by 24 mm in length. These rat apertures provide a reconstructed resolution below 
1.6 mm at 140 keV, with an average sensitivity of 1,100 cps/MBq across the field of view 
(FOV). The axial FOV is extended using a step-and-shoot helical scan of the animal, with the 
user defining a range from 24 to 270 mm according to the region to be imaged. Accordingly 
the mouse high resolution apertures comprise of 1-mm-diameter pinholes resulting in a 
resolution in the sub millimeter range.  
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Figure 3 
 
Whole body SPECT/CT of a PC3-
tumor-bearing mouse 24 hours after the 
injection of 50 MBq 111In-Bombesin.  
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After the acquisition, the data are reconstructed iteratively with the HiSPECT (Bioscan Inc., 
Washington D.C., USA) software, a dedicated ordered subsets-expectation maximization 
(OSEM) software package for multiplexing multi-pinhole reconstruction. The camera is 
calibrated with a phantom, approximately of the size of the animals, filled with a known 
activity of 99mTc such that voxel values in the reconstruction provide a proper estimate of the 
activity level without further calculation. Regions of interest (ROI) can be drawn manually 
around the object of interest; the 3D activity distribution within the ROI is then summed to 
determine the radioactivity. No correction for scatter or attenuation is performed because the 
quantification factor also corrects for attenuation within the animal. Quantification is 
performed with the INTERVIEW XP (Mediso Ltd., Budapest, Hungary) software. The 
absolute in vivo quantification is probably the most important tool to evaluate new tracers. 
The detailed evaluation of the accuracy of this function is described in chapter 4a.   
 
In various studies the capabilities of the system were evaluated (unpublished data). Depending 
on the injected activity and the imaging time a very high resolution for static images can be 
achieved. An example of a “standard” SPECT/CT of a tumor bearing mouse is shown in 
Figure 3.  
 
Using long scanning times and high resolution apertures allow even to resolve 
inhomogeneities of tracer uptake within the tumor caused by inhomogeneous distribution of 
receptors. These images can be correlated very well with ex vivo autoradiograms. An example 
is shown in figure 4.  
 
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
Beside this high resolution that is provided by pinhole SPECT, the multi-pinhole technique 
results in sensitivity comparable to parallel-hole collimators. On the one hand this allows 
injecting relatively small amounts of radioactivity and on the other hand it allows keeping the 
acquisition times or the time per projection respectively low. In turn this gives a very good 
temporal resolution. We investigated dynamically rat kidney function with 99mTc-MAG3 and 
tumor uptake of 111In-Octreoscan in a somatostatin receptor positive tumor in a rat. The time 
per scan could be kept as low as 60 seconds per scan. Up to 45 scans were acquired per study. 
The resulting time activity curves as well as an example of subsequent MIP images of a 
99mTc-MAG3 study are shown in figure 3.  
 
 
 
 
 
Correlation between ex 
vivo autoradiograms and 
in vivo SPECT slices of a 
somatostatin receptor 
positive rat pancreatic 
tumor (CA20948) after the 
injection 111In-Octreoscan. 
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Figure 5  
 
5a 
 
 
 
 
 
 
5b 
 
 
 
 
 
 
 
 
 
 
5c 
 
 
 
 
 
 
 
 
 
 
 
 
The variety of tracers available allows to look at different physiological functions in one 
animal or to follow a process over time. In a therapy study with tumor bearing rats we were 
able to monitor the animals over time. Five days after injection the biodistribution of the 
therapeutic [177Lu-DOTA0,Tyr3]-octreotide was documented. Approximately 4 weeks after 
the treatment the response to the therapy was assessed by an 111In-Octreoscan scintigraphy 
and finally before sacrificing the animals the kidney function was monitored with 99mTc-
DMSA. An example of these three scans in one animal is shown in figure 6.  
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5a. Dynamic in vivo SPECT 
images (MIP data) of rat kidneys 
after the injection of 40 MBq 
99mTc-MAG3.   
 
5b. In vivo renograms of rat 
kidneys generated with the 
NanoSPECT/CT after the 
injection of 40 MBq 99mTc-MAG3.  
 
5c. Dynamic measurement of 
111In-Octreoscan tumor uptake in 
a somatostatin receptor positive 
rat pancreatic tumor (CA20948). 
The data are generated with the 
NanoSPECT/CT in vivo.  
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Figure 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SPECT images of the identical rat with different tracers at different time points as indicated.  
 
 
In a first study, taking advantage of the NanoSPECT/CT we investigated mechanism of 
kidney damage in rats during high dose PRRT [90]. Besides small animal imaging a number 
of other molecular imaging methods along with histology using different staining were 
applied. The results of this study are shown in chapter 4b.  
 
In conclusion we believe that small animal imaging will strongly influence further preclinical 
research. It allows to follow processes over time or to monitor different functions in a single 
animal at the same time which will reduces the number of animals required and in turn it will 
save costs as well. Additionally, the situation as it is given in a patient is reflected better when 
different functions can be monitored in one animal simultaneously and as true in vivo 
investigation.   
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Therapy with [90Y-DOTA0, Tyr3]-octreotide (DOTATOC, where
DOTA  tetraazacyclododecane tetraacetic acid and TOC 
D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol)) is established for
the treatment of metastatic neuroendocrine tumors. Neverthe-
less, many patients experience disease relapse, and further
treatment may cause renal failure. Trials with 177Lu-labeled so-
matostatin analogs showed less nephrotoxicity. We initiated a
prospective study with 177Lu-DOTATOC in patients with re-
lapsed neuroendocrine tumors after 90Y-DOTATOC treatment.
Methods: Twenty-seven patients, pretreated with 90Y-DOTA-
TOC, were included. The mean time between the last treatment
with 90Y-DOTATOC and 177Lu-DOTATOC was 15.4  7.8 mo
(SD). All patients were injected with 7,400 MBq of 177Lu-DOTA-
TOC. Restaging was performed after 8–12 wk. Hematotoxicity
or renal toxicity of World Health Organization grade 1 or 2 was
not an exclusion criterion. Results: Creatinine levels increased
significantly, from 66  14 mol/L to 100  44 mol/L (P 
0.0001), after 90Y-DOTATOC therapy. The mean hemoglobin
level dropped from 131  14 to 117  13 g/L (P  0.0001) after
90Y-DOTATOC therapy. 177Lu-DOTATOC therapy was well tol-
erated. No serious adverse events occurred. The mean ab-
sorbed doses were 413  159 mGy for the whole body, 3.1 
1.5 Gy for the kidneys, and 61 5 mGy for the red marrow. After
restaging, we found a partial remission in 2 patients, a minor
response in 5 patients, stable disease in 12 patients, and pro-
gressive disease in 8 patients. Mean hemoglobin and creatinine
levels did not change significantly. Conclusion: 177Lu-DOTA-
TOC therapy in patients with relapse after 90Y-DOTATOC treat-
ment is feasible, safe, and efficacious. No serious adverse
events occurred.
Key Words: 177Lu-DOTATOC; 90Y-DOTATOC; radionuclide
therapy; somatostatin; neuroendocrine tumors
J Nucl Med 2005; 46:1310–1316
Treatment options for metastatic neuroendocrine tumors
are limited. Trials with long-acting somatostatin analogs
(octreotide or lanreotide), interferon-, or chemotherapy,
mostly 5-fluorouracil based, have shown rather low re-
sponse rates with regard to cytoreduction (1–3). However,
somatostatin analogs inhibit flushing, diarrhea, and other
symptoms of the carcinoid syndrome (4,5). A retrospective
case series in 1996 suggested that survival has increased
since the introduction of somatostatin analogs (6). In the last
few years, treatment strategies with radiolabeled somatosta-
tin analogs have shown more convincing results (7–13). The
3 most investigated radiopharmaceuticals in clinical trials
are [111In-diethylenetriaminepentaacetic acid (DTPA)0]-oc-
treotide, [90Y-DOTA0, Tyr3]-octreotide (DOTATOC, where
DOTA  tetraazacyclododecane tetraacetic acid and
TOC D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol)), and
[177Lu-DOTA0, Tyr3, Thr8]-octreotide (DOTATATE) (7–13).
Initial studies with high activities of [111In-DTPA0]-oct-
reotide were encouraging. Although partial remissions were
not found, favorable effects on symptoms were reported.
Many patients in poor clinical condition were included
(12,13). For the other 2 radiopeptides, a high overall re-
sponse rate and distinct improvement in quality of life could
be demonstrated (10,14). Although the results with these
radiolabeled somatostatin analogs seem promising, relapses
occur after a certain time in many patients (15), and further
treatment with 90Y-DOTATOC can cause renal failure (16).
According to data in the literature, the median time to
progression after treatment with 90Y-DOTATOC is 30 mo
(17,18). For 177Lu-DOTATATE, the median time to pro-
gression had not been reached at 25 mo after the start of
therapy (19).
In comparison to 90Y, which is a high-energy, pure
-emitter (Emax, 2.25 MeV), 177Lu is a low-energy -emitter
(maximum electron energy [Emax], 0.497 MeV) with a small
-component that is suitable for scintigraphic imaging (133
keV [6.5%]; 208 keV [11%]) without using a radionuclide
surrogate. Small peptides such as DOTATOC are reab-
sorbed by the proximal tubules of the kidneys (20). The
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damage that can occur after treatment with 90Y-DOTATOC
is in the glomeruli. It is conceivable that the length of the
-particles influences kidney toxicity. This hypothesis is
supported by animal experiments (21).
Renal toxicity has been identified as the dose-limiting
factor of 90Y-DOTATOC therapy (9). In a study with
[177Lu-DOTA0, Tyr3, Thr8]-octreotide, no nephrotoxicity
was found (11). Although no long-term outcome data con-
cerning nephrotoxicity after treatment with 90Y-DOTATOC
or 177Lu-DOTATATE are available, we assumed that 177Lu
might be less nephrotoxic than 90Y.
In vitro, a higher affinity to the somatostatin receptor
subtype 2 was demonstrated for Y(III)-DOTATATE than for
Y(III)-DOTATOC (22). However, because in humans a bet-
ter tumor-to-kidney-ratio was found for 111In-DOTATOC
than for 111In-DOTATATE (23), we decided to use DOTA-
TOC as a DOTA-peptide conjugate labeled to 177Lu in
patients with relapse.
We initiated a prospective feasibility study with 177Lu-
DOTATOC in patients with relapse of neuroendocrine tu-
mors after successful treatment with 90Y-DOTATOC. Be-
cause of the assumption that 177Lu-DOTATOC is less
nephrotoxic than 90Y-DOTATOC, we did not consider
World Health Organization (WHO) grade 1 or 2 renal
toxicity, based on creatinine levels, to be an exclusion
criterion, nor were patients with WHO grade 1 or 2 hema-
totoxicity excluded. Human data for 177Lu-DOTATATE
show promising results and a tolerable toxicity for injected
activities of around 22.2–29.6 GBq (600–800 mCi) in pa-
tients who are not pretreated with peptide receptor–medi-
ated radionuclide therapy (11). But for 177Lu-DOTATOC,
we could find no human data in the literature. Because our
patients were pretreated with peptide receptor–mediated
radionuclide therapy, and because no dosimetric data were
available, we started with a relatively low injected activity.
We treated all patients with a fixed activity of 7,400 MBq
(200 mCi).
MATERIALS AND METHODS
The study was approved by the local ethical committee and the
Swiss authorities. All patients gave written informed consent.
Patients
Twenty-seven patients (17 men and 10 women) were included.
The mean age ( SD) was 58  9 y. All patients had a histolog-
ically confirmed metastatic neuroendocrine tumor, which was pro-
gressive at the time of treatment. The progression was demon-
strated by CT or ultrasound in all patients. All patients were
pretreated with 90Y-DOTATOC and benefited from this treatment.
Benefit was defined as complete remission, partial remission,
minor response, or stable disease according to the WHO standard
criteria. For the partial remissions in our collective, the mean time
to progression was 15.4  6.9 mo. Many patients were pretreated
with surgery, chemotherapy, octreotide, or interferon as well.
Details are listed in Table 1.
Pretherapeutically, all patients underwent staging with CT,
111In-pentetreotide scintigraphy (OctreoScan; Mallinckrodt, Inc.),
complete blood counts, and blood chemistry. The findings of
111In-octreotide scintigraphy were strongly positive in all patients.
None of the patients had been treated with the long-acting soma-
tostatin analogs octreotide (Sandostatin LAR; Novartis) or lan-
reotide (Somatuline; Ipsen) during at least the last 6 wk before
receiving 177Lu-DOTATOC or with short-acting octreotide (San-
dostatin s.c.; Novartis) during the last 3 d before receiving 177Lu-
DOTATOC.
Radiotracer
DOTATOC was synthesized as previously described (24). For
radiolabeling DOTATOC, we used lyophilized kits containing
DOTATOC, gentisic acid, inositol, and sodium ascorbate (pH 5.0).
We added 7,400 MBq of 177LuCl3 (IDB Holland BV) to the
lyophilized DOTATOC kits and heated them for 30 min at 95°C.
After they had been cooled to room temperature, a quality control
check was performed using an analytic high-performance liquid
chromatograph (model 1050; Hewlett Packard) with a radiometric
detector (model LB 506 C1; Berthold). Additionally, the labeling
yield was determined by separation of bound and free 177Lu3
using Sep-Pak C18 cartridges (Waters). After 177Lu-DOTATOC
had been loaded onto the cartridge, the free 177Lu was eluted with
sodium acetate buffer (0.4 mol/L, pH 5.0), and bound 177Lu-
DOTATOC was then eluted with methanol. Each fraction was
measured on a -counter.
Treatment
The patients were hospitalized for 3 d in accordance with the
legal requirements for radioactivity control. A single, fixed-activ-
ity treatment protocol was used. The injected activity was 7,400
MBq of 177Lu-DOTATOC. An infusion of 2,000 mL of an amino
acid solution (Ringer’s lactated Hartmann solution, Proteinsteril
[B. Braun Medical AG] HEPA 8%, Mg 5-Sulfat [B. Braun Med-
ical AG]) to inhibit tubular reabsorption of the radiopeptide was
started 30 min before administration of the radiopharmaceutical
and was continued until up to 3 h after administration of the
radiopharmaceutical (20,25,26).
Imaging and Dosimetry
Imaging was performed with a dual-head Prism 2000 XP cam-
era (Picker) using parallel-hole, medium-energy, general-purpose
collimators. The windows were centered over both 177Lu photon
peaks (113 and 208 keV) with a window width of 20%. In 4
patients, whole-body scans for dosimetry were obtained immedi-
ately and at 4, 24, and 28 h after injection. The acquisition time for
the whole-body scans was 15 min. In all other patients, whole-
body scans and spot images were obtained after 24 and 28 h for
control of biodistribution.
To determine blood clearance, we drew blood samples from 4
patients at 5, 10, 30, and 60 min and at 12, 4, 24, and 28 h after
injection. Radioactivity in blood was measured with a -counter
(Cobra II; Canberra-Packard).
For dosimetric calculations, regions of interest were drawn
manually on the whole-body scans from anterior and posterior
projections. Those parts of the kidneys showing tumor infiltration
or superimposition were excluded from the evaluation of organ
uptake. The Odyssey XP program (Philips Electronics N.V.) was
used. Background regions were placed close to the regions of
interest for background correction. The geometric mean value
between anterior and posterior was taken and corrected for atten-
uation and physical decay. Whole-body activity acquired immedi-
ately after injection was defined as 100% of the injected activity.
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Data were expressed as percentage injected activity as a function
of time. The resulting time–activity data were fitted to a monoex-
ponential curve for the whole-body clearance and to a biexponen-
tial curve for the kidneys to calculate residence time. Published
radiation dose factors were used to calculate the absorbed doses
(27).
The activity in blood was fitted to a biexponential curve to
determine the residence time in blood. The dose to the red marrow
was calculated from the residence time in blood, assuming no
specific uptake, a uniform distribution of activity, and clearance
from red marrow equal to that from blood. A correction factor of
1 was used as described by Cremonesi et al. (28).
Evaluation of Results and Assessment of Clinical
Benefit
Pretherapeutically, patients underwent disease staging. Eight to
12 wk after peptide receptor–mediated radionuclide therapy, tumor
growth and tumor response were monitored by CT or ultrasound.
Tumor response was defined according to the WHO standard
criteria. In addition, complete blood cell and platelet counts were
obtained every 2 wk for at least 8 wk or until resolution of nadir.
Side effects were scored according to the WHO criteria.
Statistics
Paired t testing was used to determine statistical significance.
Differences at the 95% confidence level (P  0.05) were consid-
ered significant.
RESULTS
The study included 27 patients with metastasized tumors,
11 of whom had neuroendocrine pancreatic tumors and 16,
neuroendocrine tumors of other sites (7 of the small bowel,
4 of unknown primary, 2 of the rectum, 1 of the stomach, 1
of the bronchus, and 1 of the appendix). Detailed patient
characteristics are listed in Table 1.
Evaluation of Long-Term Outcome After 90Y-DOTATOC
Therapy
All patients had progressive disease before 90Y-DOTA-
TOC therapy and before 177Lu-DOTATOC therapy. One
criterion for inclusion into this study was benefit from
90Y-DOTATOC therapy. Of the 27 patients studied, we
found a partial remission in 14, a minor response in 3, and
stable disease in 10 at 3 mo after the last treatment with
90Y-DOTATOC.
The mean time between the last treatment with 90Y-
DOTATOC and the treatment with 177Lu-DOTATOC was
15.4  7.8 mo (range, 4–32 mo).
Before therapy with 90Y-DOTATOC, the mean hemoglo-
bin level was 131  14 g/L, the mean thrombocyte level
was 306  123  109/L, and the mean creatinine level was
66  14 mol/L. Before treatment with 177Lu-DOTATOC,
the level of hemoglobin was significantly lower: 117  13
g/L (P  0.0001). The thrombocyte counts (263  83 
109/L) were lower as well but did not show significant
changes. Creatinine levels increased to 100  44 mol/L.
The difference was significant (P  0.0001), although a
high SD was seen. Details are listed in Table 2.
Labeling of 177Lu-DOTATOC
The quality control testing of 177Lu-DOTATOC was done
using 2 independent systems; the labeling efficiency was
determined by analytic high-performance liquid chromatog-
raphy and ranged from 99% to 100%. When the labeling
yield was less than 99.5%, DTPA (1 mmol/L, pH 7.4) was
added.
Dosimetry
Dosimetric calculations were performed on 4 patients and
resulted in a mean whole-body absorbed dose of 413  159
mGy. The mean absorbed dose to the kidney was 3.1  1.5
Gy, and that to the red marrow was 61  5 mGy.
Treatment with 177Lu-DOTATOC
The treatment was well tolerated. No severe adverse
events occurred. Nausea and vomiting within the first 24 h
after treatment occurred in 8 patients (30%). All cases of
nausea and vomiting could be treated successfully with
domperidone and ondansetron. Some increase of pain at the
site of the tumor was experienced by 5 patients (19%)
within the first 48 h after treatment. All cases could be
controlled with analgesics. No other nonhematologic toxic-
ity was found.
As expected. 177Lu-DOTATOC showed a high specific
uptake in somatostatin receptor–positive tumors. The
-component of 177Lu allowed acquisition of scintigraphic
images of a high level of quality (Fig. 1A).
At the time of restaging, we found no change in creatinine
levels. With these findings, late nephrotoxicity cannot be
excluded definitely. But if nephrotoxicity arises, an increase
in creatinine levels has usually been found 3 mo after
treatment (16). Before treatment, 9 patients had grade 1
anemia and 1 had grade 2. Eight to 12 wk after treatment, 8
patients had grade 1 anemia, 1 had grade 2, and 1 had grade
3. The mean level of thrombocytes decreased significantly,
from 263 82 to 197 70 109/L (P 0.01). Details are
listed in Table 2.
Eight to 12 wk after treatment, 8 patients did not show a
benefit from peptide receptor–mediated radionuclide ther-
apy and continued to have progressive disease. Nineteen
patients (70%) showed a benefit: 12 with stabilization of the
disease, 5 with a minor response, and 2 with partial remis-
sion. Scans of patient 9, with a minor response, are shown
in Figure 1, and corresponding anatomic images are shown
in Figure 2. According to the referring physicians, the
general condition of the patients improved for 15 (56%),
remained the same for 11 (41%), and decreased for only
1 (4%).
The subgroup of patients who achieved partial remission
after 90Y-DOTATOC (n  14) included 2 with partial
remission, 5 with a minor response, and 7 with stable
disease after 177Lu-DOTATOC treatment. In no patient of
this subgroup did the disease remain progressive.
The overall time of follow-up was 4–17 mo (mean,
11.0  4.0 mo). The time of remission (stable disease,
minor response, or partial remission) ranged from 4 to 13
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mo (mean, 8.3  3.4 mo). Presently, 8 patients are still
without disease progression; therefore, the overall time to
progression will increase further.
DISCUSSION
The labeling of 177Lu-DOTATOC was straightforward,
and its application was safe. No serious adverse events
occurred.
The group of 27 patients was selected from patients
treated earlier with 90Y-DOTATOC; all showed stable dis-
ease, a minor response, or partial remission after treatment
but experienced relapse rather early and a short time to
progression (15  7.8 mo) The time to progression after
treatment with 90Y-DOTATOC in these patients was shorter
than has been reported in the literature (18).
The absorbed doses to normal organs, especially to the
kidneys, were low. In previous clinical trials, a cumulative
absorbed dose to the kidneys of 23 or 27 Gy was taken as
the maximum tolerated dose (11,26,29). But these values
are controversial (30) because they are derived from exter-
nal-beam radiation (31) with a potentially different mecha-
nism. The low absorbed doses are compatible with the fact
that no increase of creatinine levels was found.
When the clinical results after 177Lu-DOTATOC are cor-
related with the clinical results after 90Y-DOTATOC, a
good response after 90Y-DOTATOC (partial remission in
our patients) is obviously a positive prognostic factor for
further radionuclide treatment. Some tumors seem to be
especially suited for peptide receptor–mediated radionu-
clide therapy. Two reasons are possible: There could be a
high density of somatostatin receptors leading to a high
radiation-absorbed dose, or there could be some tumors that
are more radiosensitive than others.
The general condition of the patients was not scaled
before treatment with 177Lu-DOTATOC but was worse
than before the first treatment with 90Y-DOTATOC be-
cause all patients had a longer history of illness and
experienced progression after remission or stabilization
after 90Y-DOTATOC therapy. The total amount of in-
jected activity (fixed activity, 7,400 MBq of 177Lu-
DOTATOC) was rather low because we included patients
with an increased serum creatinine level or with a dimin-
ished hemoglobin level.
The toxicity in patients with increased creatinine or di-
minished hemoglobin levels was not different from that in
patients with normal values. We found no severe toxicity
and, especially, no increase of creatinine levels. Therefore,
we conclude that the treatment with 177Lu-DOTATOC in
cases of relapse after treatment with 90Y-DOTATOC is
feasible and safe. Clinical improvement could be observed,
and most patients benefited from the treatment.
FIGURE 1. Anterior whole-body scans of patient 9. (A) Scan
obtained 24 h after injection of 7,400 MBq of 177Lu-DOTATOC
shows several abdominal metastases (liver, spleen, and lymph
nodes). (B) Scan obtained 6 h after injection of 185 MBq 111In-
Octreoscan 6 mo after treatment with 7,400 MBq of 177Lu-
DOTATOC shows a decrease in tumor load. Especially, a re-
duction of liver metastases can be seen.
FIGURE 2. CT scans of patient 9. (A)
Nine months after treatment with 90Y-
DOTATOC and 4 wk before treatment with
177Lu-DOTATOC, CT scan shows multiple
liver metastases. (B) Corresponding CT
scan 4 mo after treatment with 177Lu-
DOTATOC shows minor response.
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With regard to the radiobiologic mechanisms of 177Lu and
90Y, the combination of the 2 radionuclides could improve the
biologic efficiency. The high-energy -emitter 90Y deposits
high doses to tumors and also to areas with low target protein
expression and to heterogeneous tumor tissue. Because of the
strong crossfire effect, parts of the tumor that either are poorly
differentiated and therefore have a low density of somatostatin
receptors or are poorly vascularized can be reached. 177Lu, on
the other hand, seems to have more favorable physical char-
acteristics for the treatment of small tumors (32–34).
Another mechanism that is not well defined is the so-
called low-dose hypersensitivity-inducible radioresistance
hypothesis as described by Joiner et al. (35). The adminis-
tration of only a low absorbed dose at a low dose rate might
be more effective in inducing tumor cell death than are
higher absorbed doses.
CONCLUSION
Treatment with 177Lu-DOTATOC of patients who were
pretreated with 90Y-DOTATOC is feasible and appears to
be safe even when patients present with grade 1 or 2
hematotoxicity or nephrotoxicity. Clinical response at a low
injected activity is promising. A good response after treat-
ment with 90Y-DOTATOC is a positive predictor for suc-
cessful treatment with 177Lu-DOTATOC.
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Abstract. [Yttrium-90-DOTA-Tyr3]-octreotide (DOTA-
TOC) and [177Lu-DOTA-Tyr3-Thr8]-octreotide (DOTA-
TATE) are used for peptide receptor-mediated radionu-
clide therapy (PRMRT) in neuroendocrine tumours. No
human data comparing these two compounds are avail-
able so far. We used 111In as a surrogate for 90Y and
177Lu and examined whether one of the 111In-labelled
peptides had a more favourable biodistribution in pa-
tients with neuroendocrine tumours. Special emphasis
was given to kidney uptake and tumour-to-kidney ratio
since kidney toxicity is usually the dose-limiting factor.
Five patients with metastatic neuroendocrine tumours
were injected with 222 MBq 111In-DOTATOC and 111In-
DOTATATE within 2 weeks. Up to 48 h after injection,
whole-body scans were performed and blood and urine
samples were collected. The mean absorbed dose was
calculated for tumours, kidney, liver, spleen and bone
marrow. In all cases 111In-DOTATATE showed a higher
uptake (%IA) in kidney and liver. The amount of 111In-
DOTATOC excreted into the urine was significantly
higher than for 111In-DOTATATE. The mean absorbed
dose to the red marrow was nearly identical. 111In-
DOTATOC showed a higher tumour-to-kidney absorbed
dose ratio in seven of nine evaluated tumours. The vari-
ability of the tumour-to-kidney ratio was high and the
significance level in favour of 111In-DOTATOC was
P=0.065. In five patients the pharmacokinetics of 111In-
DOTATOC and 111In-DOTATATE was found to be com-
parable. The two peptides appear to be nearly equivalent
for PRMRT in neuroendocrine tumours, with minor ad-
vantages for 111In/90Y-DOTATOC; on this basis, we shall
continue to use 90Y-DOTATOC for PRMRT in patients
with metastatic neuroendocrine tumours.
Eur J Nucl Med Mol Imaging (2004) 31:1257–1262
DOI 10.1007/s00259-004-1553-6
Introduction
Somatostatin receptors have been identified in high den-
sity on neuroendocrine tumours as well as on tumours of
the central nervous system, the breast, the lung and the
lymphatic tissue [1]. To demonstrate the presence of so-
matostatin receptors in vivo, scintigraphy with radiola-
belled somatostatin analogues such as [111In-DTPA-D-
Phe1]-octreotide (Octreoscan) has become the gold stan-
dard [2]. Peptide receptor-mediated radionuclide therapy
(PRMRT) has been used for several years in the treat-
ment of progressive, metastasised, somatostatin receptor-
positive tumours. Both somatostatin analogues, [90Y-
DOTA-Tyr3]-octreotide (DOTATOC) and [177Lu-DOTA-
Tyr3-Thr8]-octreotide (DOTATATE), have been used for
this purpose and have shown encouraging results [3–6].
Recently, Kwekkeboom et al. showed that 177Lu-
DOTATATE had an up to fourfold higher tumour uptake
than [111In-DTPA]-octreotide in six patients [7]. More-
over, Reubi et al. have shown that Y(III)-DOTATATE has
an approximately sevenfold higher binding affinity to the
somatostatin receptor subtype 2 (hsst2) compared with
Y(III)-DOTATOC [8], which suggests that 111In/90Y-
DOTATATE would show a higher tumour uptake in pa-
tients. However, no patient data comparing these two
compounds are available so far.
Therefore, the aim of this study was to compare 
the pharmacokinetics of 111In-DOTATOC and 111In-
DOTATATE in the same patients. Special emphasis was
placed on the mean absorbed doses for tumour, kidney
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and bone marrow since the dose-limiting organs for
PRMRT with radiolabelled somatostatin analogues are
usually the kidneys and the bone marrow [3, 4, 9]. In 
addition, 111In-DOTATOC/111In-DOTATATE was taken
as a surrogate for 90Y-DOTATOC/90Y-DOTATATE and
the calculated mean absorbed doses of 90Y-DOTATOC
were compared with the doses of this radiopeptide
known from the literature [10–13].
Materials and methods
Patients. Five male patients (age 49–73, mean 62 years) (Table 1)
with known metastatic neuroendocrine tumours were injected with
222 MBq 111In-DOTATOC and 222 MBq 111In-DOTATATE, with
an interval of 2 weeks between the administrations. In three 
patients, 111In-DOTATATE was injected first, while in two, 111In-
DOTATOC was injected first. In two patients the primary tumour
was in the pancreas. In three patients the origin of the disease was
unknown. None of the patients had received medication with so-
matostatin analogues (Octreotide s/c or LAR, Novartis Pharma;
Lanreotide, Ipsen Ltd.) within the 8 weeks before the examina-
tions. All patients had a histologically confirmed neuroendocrine
tumour and had been treated with 90Y-DOTATOC before. There
were at least 14 months between the last therapy and the beginning
of the study (14–25 months, mean 20.25 months). Metastatic dis-
ease had been confirmed in all cases by recent morphological im-
aging with magnetic resonance imaging (MRI), computed tomo-
graphy (CT) or ultrasonography. Based on these examinations, the
tumour volumes were calculated. The study was approved by the
Swiss authorities and by the local ethical committee (Ethikkom-
mission beider Basel). All patients gave informed consent.
Radiopharmaceuticals. Both somatostatin analogues, DOTATOC
and DOTATATE, were synthesised in house according to a previ-
ously published procedure [8, 14] and radiolabelled with 111In as
published previously [15]. 111In was purchased from Tyco Health-
care (Petten, The Netherlands). The labelling yield and the radio-
pharmaceutical purity were checked using C18 reversed-phase
high-performance liquid chromatography.
Imaging. All images were acquired with a dual-head gamma cam-
era Picker Prism 2000 XP (Philips, Eindhoven, The Netherlands).
The windows were centred over both 111In photon peaks (245 
and 172 keV) with a width of 20%. Parallel-hole, medium-energy
general-purpose collimators were used. For both compounds, the
same protocol was followed: dynamic imaging up to 20 min post
injection with a field of view over the kidneys and liver from the
posterior projection (80 images, 15 s per image). Whole-body
scans were obtained 1, 2, 4, 24 and 48 h after injection. The acqui-
sition time for all whole-body scans was 15 min.
Measurement of radioactivity in blood and urine. Blood samples
were drawn 10, 20, 30 and 60 min and 2, 4, 24 and 48 h after in-
jection. Urine was collected in four intervals: 0–2, 2–4, 4–24 and
24–48 h after injection. Radioactivity in blood and urine was mea-
sured with a gamma counter (Cobra II Autogamma, Packard, A
Canberra Company).
Pharmacokinetics and dosimetry. Regions of interest (ROIs) were
drawn manually on the whole-body scans from the anterior and
posterior projections for the whole body, the kidneys, the spleen,
the liver, the bladder and tumour lesions. The Odyssey XP pro-
gram was used. Background regions were placed close to the ROIs
for background correction. Parts of the organs showing tumour in-
filtration or superimposition were excluded from the evaluation of
organ uptake. The geometric mean value, between anterior and
posterior, was taken and corrected for attenuation and physical de-
cay. Whole-body activity acquired 1 h after injection was defined
as 100% of the injected activity (IA). The patients did not empty
the bladder during this period. All data for the whole body, organs
and tumour lesions were expressed in %IA. A compartment model
as described previously was used to calculate the residence time
from the time-activity data resulting from the scans [10]. The 
activity in blood was fitted by three exponential curves. The resi-
dence times were determined using these data and the respective
half-lives of 111In and 90Y. Assuming no specific uptake in the red
marrow, a uniform distribution of the activity, and that the red
marrow clearance was the same as in blood, the dose to the red
marrow was calculated with a correction factor of 1 from the resi-
dence time in blood as published previously [10].
Statistics. Paired t test was used to determine statistical signifi-
cance. Differences at the 95% confidence level (P<0.05) were
considered significant.
Results
Patients showed no clinical adverse reactions and no
side-effects after the intravenous injection of 111In-
DOTATOC or 111In-DOTATATE.
Pharmacokinetic studies
Figure 1 displays the mean plasma radioactivity (and
standard deviation) expressed as %IA. The clearance of
both peptides was fast. The time-activity in blood could
be fitted by three exponential curves. In all patients and
for both radiopeptides, the activity in blood decreased to
less than 10% within the first 4 h. 111In-DOTATOC
showed a somewhat slower clearance initially. After 24
and 48 h, a slightly higher amount of 111In-DOTATATE
was found in the blood of all patients. The mean resi-
dence time (τ) was 1.178 h (SD±0.19 h) for 111In-DOTA-
TOC and 1.156 h (SD±0.32 h) for 111In-DOTATATE.
Therefore, the mean absorbed dose to the red marrow
was not significantly different between the two com-
pounds (Table 2). Only a small interpatient variability
was found (Table 3).
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Table 1. Patient details
Patient Age (yrs) Histology and primary tumour
1 69 Neuroendocrine tumour of the pancreas
2 65 Neuroendocrine tumour of unknown origin
3 73 Neuroendocrine tumour of unknown origin
4 53 Neuroendocrine tumour of unknown origin
5 49 Neuroendocrine tumour of the pancreas
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Cumulative activity excreted into the urine was high-
er for 111In-DOTATOC in all samples and all patients
(Fig. 2). For all periods (0–2, 2–4, 4–24 and 24–48 h) the
difference was significant (P<0.05).
Biodistribution and dosimetry
The distribution pattern of 111In-DOTATATE was initially
comparable to the pattern using 111In-DOTATOC. In four
of the five patients a distinct specific uptake in tumour
sites was seen after approximately 2 min. Also, there was
fast visualisation of the liver, kidneys and spleen. The fifth
patient showed no tumour uptake with either compound
due to an impressive decrease in tumour load after 90Y-
DOTATOC therapy. In this patient, only two small liver
metastases <1 cm were found on a recent CT scan.
We found higher mean absorbed doses to the kidneys
and liver for 111In-DOTATATE. The calculated difference
for 90Y, when taking 111In as a surrogate, was significant
in the liver (P<0.05) but not in the kidneys (P=0.135).
The dose to the spleen showed a high interpatient vari-
ability. Although in three patients the mean absorbed
dose to the spleen for 111In-DOTATATE was higher 
(Table 2), the difference did not reach significance
(P=0.205). The calculated absorbed doses for 90Y-
DOTATOC (taking 111In-DOTATOC as the surrogate) for
the various organs are comparable with the doses known
from the literature [10–12]. Our values, along with liter-
ature data, are shown in Table 3.
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Table 2. Mean absorbed doses (mGy/MBq) for 90Y-DOTATOC (TOC) and 90Y-DOTATATE (TATE) derived from biodistribution data in
five patients using the 111In-labelled peptides
Patient Kidneys Liver Spleen Red Marrow
TOC TATE TOC TATE TOC TATE TOC TATE
1 2.95 3.53 0.88 1.31 15.5 13.4 0.15 0.15
2 3.15 3.62 0.82 2.39 1.71 3.3 0.17 0.16
3 3.60 3.62 1.33 2.16 4.8 7.74 0.17 0.20
4 2.59 3.58 1.15 1.34 4.71 7.98 0.19 0.16
5 1.91 5.17 0.41 1.18 6.12 18.5 0.15 0.13
Mean ± SD 2.84±0.64 3.90±0.71 0.92±0.35 1.68±0.56 6.57±5.25 10.18±5.87 0.17±0.02 0.16±0.03
P value 0.135 0.031 0.205 0.591
Table 3. Comparison of mean absorbed doses (±SD) (mGy/MBq) for 90Y-DOTATOC derived from 111In-DOTATOC and 86Y-DOTATOC
Forrer et al. this study Cremonesi et al. [10] Förster et al. [11] Krenning et al. [12]
Derived from 111In-DOTATOC 111In-DOTATOC 86Y-DOTATOC 86Y-DOTATOC
Kidney 2.84 (±0.64) 3.31 (±2.22) 2.73 (±1.41) 2.1 (±0.78)
Liver 0.92 (±0.35) 0.72 (±0.57) 0.66 (±0.15) –
Spleen 6.57 (±5.25) 7.62 (±6.30) 2.32 (±1.97) 1.83 (±1.45)
Red marrow 0.17 (±0.02) 0.03 (±0.01) 0.049 (±0.002) 0.11 (±0.06)
Fig. 1. Blood clearance expressed as percentage of the injected 
activity (%IA) in the blood (mean ± SD)
Fig. 2. Cumulative activity excreted into the urine expressed as
%IA (mean ± SD)
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Overall, nine metastases could be evaluated in scinti-
graphic images and correlated with a lesion on CT, MRI
or sonography. In five of the nine lesions, a somewhat
higher mean absorbed dose (mGy/MBq) was found for
111In-DOTATOC; however, high variability between the
lesions was observed (Table 4).
Since most often the dose-limiting organ in therapy
with radiopeptides is the kidneys, the absorbed dose ratio
of lesion to kidneys will determine the therapeutic win-
dow. Due to the high variability in mean absorbed doses
in the tumours, we found a high variability in the dose
ratios as well. However, in seven out of nine lesions,
111In-DOTATOC showed a higher ratio and the differ-
ence in mean values almost reached significance
(P=0.065) (Table 4).
In two patients, whole-body scans 4, 24 and 48 h after
injection showed better visualisation of liver metastases
with 111In-DOTATOC. In the other three patients, the
scans were visually identical. The better demarcation
was due to the lower uptake in the normal liver. Findings
in one of the patients with better demarcation of the liver
metastases with 111In-DOTATOC are shown in Fig. 3.
Discussion
In this study, both radiopeptides, 111In-DOTATOC and
111In-DOTATATE, showed the expected high specific up-
take in somatostatin receptor-positive tissue. Visually,
the results obtained with the two compounds were com-
European Journal of Nuclear Medicine and Molecular Imaging Vol. 31, No. 9, September 2004
Fig. 3. Whole-body scans of
patient no. 2, 4 h after injection
of 222 MBq 111In-DOTATOC
(left) and 111In-DOTATATE
(right). Better visualisation of
the tumours in the liver can be
seen in 111In-DOTATOC
Table 4. Mean absorbed tumour doses (mGy/MBq) for 90Y-DOTATOC and 90Y-DOTATATE derived from biodistribution data in nine
tumours using the 111In-labelled peptides and the respective tumour-to-kidney ratio
Patient Lesion (localisation) Tumour doses (mGy/MBq) Tumour-to-kidney ratio
DOTATOC DOTATATE DOTATOC DOTATATE
1 1 (ln) 12.23 12.12 4.15 3.43
2 (li) 33.34 24.26 11.30 6.87
2 3 (li) 2.88 4.60 0.91 1.27
4 (li) 6.31 8.19 2.00 2.26
4 5 (b) 2.80 1.73 1.08 0.48
6 (li) 41.66 55.54 16.08 15.51
7 (li) 26.72 15.93 10.32 4.45
8 (li) 15.77 12.13 6.09 3.39
5 9 (b) 2.37 6.15 1.24 1.18
Mean ± SD 16.01±14.64 15.63±16.40 5.91±5.48 4.32±4.36
P value 0.879 0.065
(ln), Abdominal lymph node; (li), liver; (b), bone
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parable, although better visualisation of some liver me-
tastases was found with 111In-DOTATOC. The dosimetric
analyses showed small differences between the radiopep-
tides, but a significantly higher mean absorbed dose to
the liver was found for 111In-DOTATATE, and a
favourable tumour-to-kidney ratio (P=0.065) was calcu-
lated for 111In-DOTATOC. These findings were unex-
pected since data from animal models have shown a
more favourable biodistribution for DOTATATE-derived
radiopeptides [16]. Because the total administered thera-
peutic dose with radiolabelled somatostatin analogues is
determined by tumour-to-kidney mean absorbed dose ra-
tios (and/or tumour-to-red marrow absorbed dose ratios),
these ratios are the most important parameters for thera-
peutic success. Slightly better results were found for
111In-DOTATOC in three of the four patients with well-
defined uptake in metastases.
In this study, we used 111In as a surrogate for 90Y, as
we assume high similarity between the tracers although
differences in pharmacological parameters have been
shown if DOTATOC is labelled with 67Ga/68Ga instead
of 111In [15]. In addition, de Jong et al. [17] showed dif-
ferences in the biodistribution of 111In-DOTATOC and
90Y-DOTATOC in rats bearing the CA 20948 tumour. 
On the other hand, Froidevaux et al. [18] showed an 
essentially similar performance of 111In-DOTATOC and
90Y-DOTATOC when using the AR4-2J bearing mouse
model.
The mean absorbed doses calculated for 90Y-DOTA-
TOC are comparable with the absorbed doses published
in the literature so far [9–13] (Table 3), confirming the
accuracy of our methodology. Although the absorbed
doses calculated for the red marrow were higher than the
doses reported by Cremonesi et al. [10] and Förster et al.
[11], they are comparable with the doses published by
Krenning et al. [12] (Table 3).
A high interpatient absorbed tumour dose variability
was found, which is not unexpected as receptor densities
vary markedly among patients and tumours. This fact is
well known from the literature [10–13].
A better tumour-to-kidney absorbed dose ratio can be
achieved by co-infusion of amino acids, especially lysine
and arginine [13, 19–21]. It is unclear whether the results
obtained in comparing 111In-DOTATOC and 111In-
DOTATATE would be the same if the measurements
were to be performed with co-infusion of amino acids.
The difference in charge (positive overall charge of 111In-
DOTATOC and neutral charge of 111In-DOTATATE)
might lead to different results with regard to the kidney
absorbed dose after amino acid co-infusion.
The accuracy of the absolute values obtained by 
organ dosimetry using gamma-scintigraphy may still be
limited owing to many potential sources of error. How-
ever, since the main aim of this study was to compare
two compounds in the same patients with the same meth-
ods, this would not have affected the reliability of the
findings.
We could not confirm the assumption, based on ani-
mal experiments, that 90Y-DOTATATE may have more
favourable characteristics for PRMRT compared with
90Y-DOTATOC. Therefore, we will continue treatment
with 90Y-DOTATOC.
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Abstract 
Purpose: Adequate dosimetry is mandatory for effective and safe peptide receptor 
radionuclide therapy. The radiation-dose to the bone marrow can be calculated from the 
residence time of the radiopeptide in the blood, but it might be underestimated since stem 
cells express somatostatin-receptors. We verified the blood-method by comparing the results 
with bone marrow aspirations. Also, we compared other models, taking into account the 
radioactivity in source organs and the remainder of the body. Methods: Bone marrow 
aspirates were drawn in 15 patients after treatment with [177Lu-DOTA0,Tyr3]octreotate. 
Radioactivity in the bone marrow was compared with radioactivity in the blood drawn 
simultaneously. The nucleated cell fraction was isolated from the bone marrow aspirate and 
radioactivity was measured. Furthermore, the absorbed dose to the bone marrow was 
calculated from the remainder of the body, with and without the additional radioactivity from 
source organs. All results were correlated to the change in platelet counts 6 weeks after 
treatment. Results: Strong linear correlation and high agreement in measured radioactivities 
between bone marrow aspirates and blood was found (r=0.914, p<0.001). No correlation 
between any of the calculated absorbed doses and the change in platelets was found. The best 
relation was found for the radioactivity in the nucleated cells of the bone marrow aspirate. 
Conclusions: There is a high agreement between the radioactivities in the bone marrow 
aspirate and blood. Neither the models had a significant correlation with the change in platelet 
counts. For the prediction of haematological toxicity many other factors may be crucial as 
well.   
 
 
Keywords:  
Dosimetry, bone marrow, [177Lu-DOTA0,Tyr3]octreotate, therapy, somatostatin receptor 
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Introduction   
 
Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues, such 
as [90Y-DOTA0,Tyr3]octreotide (90Y-DOTATOC) or [177Lu-DOTA0,Tyr3]octreotate, is an 
effective treatment in patients with metastatic neuroendocrine tumours [1-6]. The dose-
limiting organs with this treatment are usually either the kidneys or the bone marrow [7-10].  
 
Haematological toxicity due to the radiation absorbed dose to the bone marrow occurs with 
most radionuclide therapies, like for instance therapy with 186Re-hydroxyethylidene 
diphosphonate (HEDP) for bone metastases of prostate carcinoma, therapy with radiolabeled 
antibodies for Non-Hodgkin Lymphoma, and 131I-metaiodobenzylguanidine (MIBG) therapy 
for neuroblastoma. The bone marrow toxicity with 186Re-HEDP is mainly due to the bone 
seeking nature of this radiopharmaceutical, whereas bone marrow toxicity with radiolabeled 
antibodies or 131I-MIBG results from the circulation of the radioactivity in the blood and its 
retention in organs, tumours and in the remainder of the body [11-14].  
 
For radiolabeled somatostatin analogues, the absorbed dose to the bone marrow is estimated 
with the aid of the MIRD scheme [15, 16]. Contributions to the red marrow dose arise from 
the activity in the marrow tissue itself (self-dose), from activity in source organs, and/or 
activity in the whole body (cross dose) :  
 
Drm =  ÃrmSrm←rm + Σ ÃhSrm←h + ÃrbSrm←rb 
 
with S(RM←RM) the self-dose S-factor and S(RM←RB) the cross-dose S-factor for the 
radiation from the remainder of the body. The residence time of the radiopharmaceutical in 
the bone marrow τRM is calculated from the residence time in the blood. Taking into 
consideration the red marrow to blood activity concentration ratio (RMBLR), a correction 
factor can be added depending on the vector used for treatment [17]. This method was 
validated by bone marrow aspirations for antibodies but not for radiopeptides [18, 19]. In 
addition, especially for radiolabeled antibodies several more sophisticated methods have been 
developed recently, taking into account the patient-specific bone marrow concentration and 
contribution of other organs [14, 16, 19-21].  
 
Relevant results were shown using 86Y as a surrogate for 90Y to calculate the residence time in 
the red marrow by PET before treatment with 90Y-DOTATOC. A region of interest (ROI) was 
drawn around a segment of the thoracic spine and rescaled for the whole red marrow mass 
using the standard fraction of active red marrow present in the thoracic spine [22].  
 
Recently a comparable method showing relevant results as well was presented for iodinated 
antibodies. Instead of a PET scan patients underwent a SPECT/CT during therapy [23]. 
Acquiring a CT and using an integrated SPECT/CT camera allows placing the ROIs 
anatomically more accurately than using a SPECT alone. This is especially important in 
radiopharmaceuticals, e.g. most radiopeptides, which do not present sufficiently high bone 
marrow uptake to be indisputably identified on the scans. In addition the CT provides an 
attenuation map that can be used to apply an attenuation and scatter correction. With three 
SPECT scans at different time points after therapy we investigated the feasibility of this 
method in a therapeutic setting.  
 
The method calculating the absorbed radiation dose in the bone marrow from the residence 
time in the blood is the easiest to apply in daily clinical practice. It deals with the assumption 
h 
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of no specific uptake of the radiolabel in the bone marrow. Since certain haematological cells 
(lymphocytes, monocytes) and haematopoietic progenitor cells express somatostatin 
receptors, mainly subtype 2 [24-26], this assumption may result in an underestimation of the 
absorbed radiation dose to the bone marrow. It is not known whether in patients a 
significantly higher radioactivity in the bone marrow, compared to the blood, may be present 
[17].  Also, the method using the whole body retention, with or without taking into account 
the contribution from the blood and/or source organs to calculate the bone marrow residence 
time could be more accurate. An overview of the parameters required and the advantages and 
disadvantages of the most commonly used methods for bone marrow dosimetry is given in 
Table 1.  
 
Reliable dose estimation for the bone marrow is mandatory for several reasons. In order to 
achieve a maximum anti-tumour effect, patients should be treated with the highest justifiable 
dose of the radiopharmaceutical that does not cause serious toxicity. Many studies with 
radiolabeled somatostatin analogues showed that the toxicity is generally mild and transient 
[1-3, 6]. It should however not be neglected that in a phase 1 study with [111In-
DTPA0]octreotide 3 out of 50 patient developed a myelodysplastic syndrome (MDS) which 
was probably related to the therapy [27]. Calculations from these data resulted in an estimated 
radiation absorbed dose for the bone marrow of approximately 3 Gy. In another study with 
[177Lu-DOTA0,Tyr3]octreotate, one MDS was observed in a patient who had had 
chemotherapy with alkylating agents 2 years before study entry [28]. In the latest update of 
our own records of roughly 500 patients treated with [177Lu-DOTA0,Tyr3]octreotate, 3 
patients (including the patient mentioned before) developed MDS (unpublished data). To 
avoid hypoplasia, a maximum absorbed dose of 2 Gy to the bone marrow is generally 
accepted [29, 30]. At a total body dose of 2 Gy the probability for developing leukaemia is 
approximately 2% [31]. In radioiodine therapy of metastatic thyroid cancer a threshold of 2 
Gy to the blood as surrogate for bone marrow has been maintained since the pioneering work 
of Benua and co-workers in 1962 [32]. More recent work has set this limit to even 3 Gy, by 
using more patient-specific dosimetry techniques [33]. Nevertheless even if this limit is not 
exceeded the risk for the patient to develop a MDS can not be excluded completely, but an 
accurate estimation of the absorbed dose to the bone marrow will help to find an adequate 
dosage.  
 
To perform bone marrow dosimetry in the clinical routine, the method has to be easily 
applicable. We compared the radioactivity in the bone marrow aspirate with the radioactivity 
in the blood. In addition we determined the difference of radioactivity in the nucleated cell 
fraction of the bone marrow, including the stem cells, versus that in the blood to demonstrate 
a potential difference which could be attributed to the specific binding of the radiopeptide to 
somatostatin receptor-positive cells of the bone marrow. Finally the calculated absorbed doses 
to the bone marrow calculated from the blood, the remainder of the body, with or without 
taking into account the contribution from the blood and/or source organs, and from the 
SPECT scans were correlated with the change in the platelets counts 6 weeks after the 
treatment.  
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Table 1 
Calculation method 
for the absorbed dose 
to the red marrow 
Experimental data to 
be collected / 
measured 
Advantages Disadvantages / uncertainties  
From the blood Approx. 5  blood samples 
Easy and cheap to 
perform; low 
discomfort level for 
patients; no inter-
observer variability 
Use of standard 
volumes for blood 
From the remainder 
of the body 
Urine; Images at 
approx. 3 time points Non invasive  
Urine collection is a 
source of errors; time 
consuming; inter-
observer variability; 
difficult quantitative 
determination     
From a bone marrow 
aspiration 
One bone marrow 
aspiration 
Real information 
from the bone 
marrow; no inter-
observer variability 
The time dependency 
is not known; highly 
invasive; discomfort 
for the patients; time 
consuming; costly 
 
From PET-scans 
with a ROI around a 
segment of the 
thoracic spine 
PET scans at approx. 
3 time points Non invasive 
PET surrogate 
necessary; can only 
be done 
pretherapeutically; 
additional 
examination; not 
quantitative 
concerning partial 
volume effect, 
scattering  
From SPECT/CT-
scans with a ROI 
around a segment of 
the thoracic spine 
SPECT/CT scans at 
approx. 3 time points Non invasive 
SPECT/CT 
necessary; ; not 
quantitative 
concerning partial 
volume effect, 
scattering; validated 
only for radiolabeled 
antibodies  
 
Table 1 gives an overview over the parameters that need to be collected / measured and the 
advantages and disadvantages for the two most common methods to calculate the absorbed 
dose to the red marrow in peptide receptor radionuclide therapy. In addition the same 
information is given for the calculation of the absorbed dose by a bone marrow aspiration.  
For antibodies a combination of the first and second method have been performed (13).
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Material and Methods 
 
Patients 
Fifteen patients with somatostatin receptor-positive neuroendocrine tumours were studied. All 
patients were admitted to our clinic for PRRT with [177Lu-DOTA0,Tyr3]octreotate and 
fulfilled the inclusion criteria as previously described [6]. None of the patients had known 
bone metastases.  
All patients gave written informed consent to participate in the study, which was approved by 
the medical ethical committee of the hospital.  
 
Comparison of the radioactivity in the bone marrow and nucleated cell fraction with the 
radioactivity in the blood 
In addition to the examinations, the treatment, and the scans that are performed routinely after 
the first treatment cycle, patients underwent a bone marrow aspiration from their iliac crest 4 
days (7 patients), 7 days (7 patients) or 8 days (1 patient) after the treatment. A rough 
differential count of cells was performed on the bone marrow samples to prove the presence 
of a sufficient number of bone marrow cells and the samples were analyzed for 
haematological abnormalities. The volume of the aspirate was recorded and the radioactivity 
was measured in a gamma counter (Perkin Elmer, Groningen, the Netherlands). One patient 
(aspiration 4 days after treatment) was excluded because no bone marrow could be aspirated. 
In all patients, a blood sample was drawn simultaneously to determine the radioactivity in the 
blood. 
 
Part of the blood samples and of the bone marrow samples were purified for the mononuclear 
cells including stem cells (bone marrow only). The samples (blood: 8 - 48 mg; 26 ± 12.2 mg 
(mean ± SD); bone marrow: 2 - 49 mg; 22 ± 16.6 mg) were diluted with 5 ml Dispase (Roche 
Diagnostics, Almere, the Netherlands) and mixed for 20 minutes to suspend the cells. Then 
the samples were diluted with 50 ml phosphate buffered saline (PBS) (pH = 7.4) and in total 3 
times centrifuged for 10 minutes at 2500 rpm (≡ 60xg) each time. In between, the samples 
were washed with 50 ml PBS after every step. The mononuclear cells, including the stem cells 
in the samples from the bone marrow, were isolated by Ficoll Paque gradient sedimentation 
(density = 1.077 g/ml) (GE Healthcare Europe GmbH, Diegem, the Netherlands). Afterwards 
the weight of the cell pellets was determined and the radioactivity was measured in a gamma 
counter.  
 
Bone marrow dosimetry 
For all patients the cumulated activity in the bone marrow was estimated with different 
methods: 
The distribution in the remaining tissue of the body besides organ and tumour uptake is 
assumed to be homogeneously distributed in the remainder of the body [34]. In addition, cross 
radiation from organs and tumours as well as blood can be taken into account. Lastly, the 
activity concentration in the red marrow can be assumed to be equal to the activity 
concentration measured in the plasma [35]. 
Also, quantitative imaging of the radioactivity uptake in the thoracic spine at several time-
points can give an estimate of the total bone marrow kinetics by rescaling these values 
according to the average fraction of active marrow in the observed regions [36]. 
 
Bone marrow dosimetry using different models 
At three different time points between 24 and 168 hours after the administration of [177Lu-
DOTA0,Tyr3]octreotate, scans of tumour deposits, liver, kidney, spleen and bladder were 
acquired using a dual head camera (Picker Prism 2000 XP, Philips, Eindhoven, The 
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Netherlands). For all quantitative analyses of planar scans and SPECT, only the higher energy 
peak of 177Lu was considered, i.e. the energy window was set at 208 keV ± 10%. Regions of 
interest were drawn manually with the Odysse XP software around visible tumours, the liver, 
the kidneys, the spleen and the bladder. The radioactivity in these organs and in the tumours 
was determined as described previously [37]. Attenuation correction was applied using the 
data from the pretherapeutical CT scan. Urine was collected up to 24 hours after treatment 
and the radioactivity was measured in the gamma counter. From these data the radioactivity in 
the remainder of the body (i.e. total body minus source organs and minus excreted 
radioactivity) was calculated, taking into account the fact that the radioactivity was 
overestimated since the urine was collected for 24 hours only. In 2 patients the determination 
of radioactivity in the remainder was not possible. Assuming the bone marrow being part of 
the remainder of the body, the absorbed dose to the bone marrow was calculated. Also, the 
contribution of source organ irradiation and/or blood radioactivity was additionally 
investigated. 
The bone marrow dosimetry using the residence time of the radiopeptide in the blood was 
based on at least 5 blood samples per patient drawn between 0 and 168 hours post injection. 
Assuming no specific uptake in the red marrow, a uniform distribution of the activity, and that 
the red marrow clearance was the same as in blood, the dose to the red marrow was 
calculated. Additionally the residence time of the radiopharmaceutical in tumour and organs 
(liver, kidneys and spleen) was calculated from planar scans at three different time points 
between 24 and 168 hours after the administration of [177Lu-DOTA0,Tyr3]octreotate. Due to 
overlap of these tumours and organs in all patients, this was regarded as one single source. 
Using OLINDA, the cross-dose from this source was added to the absorbed dose to the red 
marrow calculated from the blood. The results were compared with the dose calculated from 
the blood alone and it was correlated with the change in platelets as well.  
 
Bone marrow dosimetry using SPECT scans 
In addition, at three different time points between 24 and 168 hours after treatment, SPECT 
scans of the thorax were acquired (energy window 208 keV ± 10%, Matrix 128 x 128, 120 
projections, 20 sec/Projection) .  
 
Correlation with the haematological response 
Six weeks after the treatment, blood was drawn from 13 patients to determine haematological 
toxicity after the treatment. For one patient no blood results were available. All values were 
correlated with the decrease in platelet counts expressed as percentage of the pretherapeutic 
value. The results of the bone marrow (full bone marrow and nucleated cell fraction) 
radioactivity were corrected for physical decay in order to compare the inter-individual values 
of the samples drawn at different time points. Similarly, calculated absorbed dose to the bone 
marrow from the remainder of the body, and from the residence time in the blood (with and 
without the dose from the source organs) were correlated with the decrease of platelet counts.   
 
Statistics 
To correlate the results, Pearson’s correlation coefficient was calculated. A p-value ≤0.05 was 
considered significant.  
 
 
Results  
 
The treatment with [177Lu-DOTA0,Tyr3]octreotate was well tolerated by all patients and no 
serious adverse events occurred. The injected radioactivity ranged from 7.26 to 7.75 GBq 
(7.47 ± 0.10 GBq; mean ± SD). On the post-therapeutic scans all patients showed the 
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expected distribution of the radiopharmaceutical with specific uptake in all known tumours. 
No patient had known or visible bone metastases.  
 
The bone marrow aspiration was uneventful. One patient had a dry tap. The volume of bone 
marrow that was aspirated in the other patients ranged from 1 to 9.2 g (5.3 ± 2.9 g). 
Simultaneously a tube of blood of 2.8 to 7.3 g (5.8 ± 1.3 g) was drawn. Smears were made 
from the bone marrow aspirate. A differential count was performed to establish the numbers 
of immature (bone marrow) and mature nucleated cells. The fraction of immature cells ranged 
from 25 to 80% (51 ± 15%) indicating that the purified aspirations consisted of a considerable 
amount of bone marrow and that the contamination with blood was moderate. A typical 
example of a purified bone marrow smear is shown in Figure 1.   
 
Figure 1 
 
 
 
 
 
 
 
 
 
Typical example of a smear of one of the bone marrow aspirations. It shows a mixture of 
immature nucleated cells originating from the bone marrow as well as red blood cells and 
mature nucleated cells originating from peripheral blood.  
 
The radioactivity in the full bone marrow samples ranged from 850 to 4473 Bq/ml (2216 ± 
899 Bq/ml). The radioactivity in the blood ranged from 1077 to 6451 Bq/ml (2437 ± 1324 
Bq/ml). Fitting the correlation line through the origine (0,0) as it seems right from a 
theoretical point of view, a strong, significant, linear correlation between the radioactivity 
determined in the blood and in the bone marrow aspirate was found (y=1.13x, r = 0.90, p < 
0.001) (Figure 2). This results in a mean Red Marrow over Blood Ratio of 0.88 (value not 
significantly different from 1). Both qualitatively and quantitatively the results showed strong 
agreement over a whole range of activities at the three different time points.  
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correlation between the activities measured in the bone marrow aspirate and the activities 
measured in the blood at the same time points in Bq/ml. The straight line is the linear 
regression line: r = 0.914, p < 0.001. The slope of the regression line is 1.35 indicating that 
also the absolute values of the measured activities are comparable.  
 
 
The absorbed dose to the bone marrow calculated from the residence time in the blood, from 
the residence time in the remainder of the body, from both and from both together with the 
cross radiation from source organs as well as the change in platelets counts after 6 weeks are 
listed in table 2. The contribution of the remainder of the body to the red marrow dose was 
substantial in relation to the contribution of the blood alone, whereas the additional 
contribution from source organs was relatively insignificant. 
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Table 2 
Patient A B C D 
Drop in 
platelet counts 
6 weeks after 
therapy [%] 
1 17 12 29 39 40 
2 24 21 44 58 8 
3 43 123 165 173 40 
4 17 83 100 107 16 
5 21 22 41 53 4 
6 36 79 114 127 - 
7 29 0 29 68 -9 
8 38 29 65 71 -9 
9 29 128 155 - 47 
10 29 429 455 466 8 
11 41 69 109 114 27 
12 19 31 50 61 32 
13 30 31 61 74 28 
14 17 39 56 64 21 
 
 
A: Absorbed dose to the red marrow [mGy] after the injection of 7400 MBq  
[177Lu-DOTA0,Tyr3]octreotate, calculated from the residence time in the blood 
 
B: Absorbed dose to the red marrow [mGy] after the injection of 7400 MBq  
[177Lu-DOTA0,Tyr3]octreotate, calculated from the residence time in remainder of the body 
 
C: Absorbed dose to the red marrow [mGy] after the injection of 7400 MBq  
[177Lu-DOTA0,Tyr3]octreotate, calculated as a combination of the dose to the red marrow 
from the blood and the remainder of the body 
 
D: Absorbed dose to the red marrow [mGy] after the injection of 7400 MBq  
[177Lu-DOTA0,Tyr3]octreotate, calculated as a combination of the dose to the red marrow 
from the blood, the remainder of the body and taking into account the cross radiation from 
source organs (tumours, liver, kidneys and spleen) 
 
 
No or merely very faint uptake in the bone marrow could be seen on the SPECT scans of the 
thorax. Bone marrow to background (ROI placed into the lungs) ratios between 1 and 1.8 
were found. Therefore it was not possible to place a ROI reliably and consequently no 
absorbed dose to the bone marrow was calculated from SPECT scans. An example of 
transaxial SPECT slices of one patient is shown in Figure 3. 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Typical example of transverse SPECT slices through the thorax, obtained 24h after therapy 
with 7.4 GBq [177Lu-DOTA0,Tyr3]octreotate. Note that no clear uptake over the spine area is 
found.  
 
No correlation was found between any of the calculated absorbed doses to the bone marrow 
and the decrease in platelets, expressed as percentage of the pre-treatment value.  
 
The relation between the activity in the full bone marrow aspirate and the drop in platelet 
counts was poor (r = 0.35, p = 0.24) (Figure 4). However, the relation between the absorbed 
doses calculated with the different methods and the decrease in platelet counts was less 
significant. The correlations were r=0.07 for the absorbed dose calculated from the blood and 
r=0.12 for the absorbed dose calculated from the remainder of the body. Taking into account 
both doses resulted in r=0.07 and including the cross radiation from source organs resulted in 
r=0.06.  
 
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correlation between the radioactivity per ml in the bone marrow aspirate with the drop of 
thrombocytes expressed as % of drop from the value measured before the treatment. The 
activities measured in the bone marrow were decay corrected to the theoretical value at day 
8. The straight line is the linear regression line: r = 0.35, p = 0.24.   
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The ratio of radioactivity in the isolated mononuclear cell fraction of the bone marrow to the 
isolated mononuclear cell fraction of the blood, obtained at the same day , yielded  highly 
variable results. We found ratios ranging from 0.29 to 536 (59.3 ± 143.6). In three patients a 
higher radioactivity could be found in the mononuclear cells isolated from the blood whereas 
11 patients showed a higher radioactivity in the mononuclear cells isolated from the bone 
marrow.  
 
For 11 patients the radioactivity in the isolated mononuclear cell fraction, microscopically 
containing a mixture of immature and mature cells, could be weight-corrected. In the other 3 
patients, the isolated fraction could not be weighed reliably, because of the small number of 
isolated cells. Weight-corrected ratios of the radioactivity in the isolated cell fraction of the 
bone marrow to the isolated cell fraction of the blood ranged from 0.54 to 133.41 (19.4 
±38.6). Only one patient showed a higher radioactivity in the isolated cell fraction per gram of 
the blood. The correlation coefficient between the radioactivity per gram in the nucleated cell 
fraction of the bone marrow aspirate and the drop in platelet counts after the treatment was r = 
0.51 (p = 0.13) (Fig 5). From our study this was the best relation that could be obtained.   
 
 
Figure 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correlation between the radioactivity per gram measured in the isolated mononuclear cell 
fraction of the bone marrow aspirate with the drop of platelet counts after the treatment. The 
straight line is the linear regression line: r = 0.51, p = 0.13.  
 
 
Discussion  
 
Accurate bone marrow dosimetry is mandatory for safe PRRT. All methods available have 
certain disadvantages: aspiration of bone marrow is costly, time consuming and it is an 
invasive procedure associated with a high level of discomfort for the patients. The diverse 
models also all have their theoretical limitations: Calculating the dose to the red marrow from 
the residence time in the blood deals with the assumption that no specific binding of the 
radiolabeled somatostatin analogue occurs in the bone marrow. Also, the determination of the 
radioactivity in the remainder of the body depends on accuracy in urine collection, which is 
subject to errors.  Besides these considerations, it should be considered that at present none of 
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the diverse models to estimate the dose to the bone marrow has been actually confirmed with 
toxicity data, be it thrombocytopenia or the occurrence of MDS. Apart from the risk for the 
patients to develop MDS the most essential issue of bone marrow dosimetry is to predict or 
better to avoid severe haematological toxicity caused by PRRT.  
However, the dose to the red marrow is only one of several factors influencing the 
haematological toxicity after PRRT. A high inter patient variability in the haematological 
response after PRRT has been found and also previous therapies can highly influence the 
results [22, 29]. Using different radiopharmaceuticals, some investigators have found a 
correlation between haematological toxicity and injected dose of radioactivity [13, 14], 
whereas others did not find such a correlation [20].  
 
It is possible that additional factors like age and sex of the patients might influence the 
haematological toxicity as well although in a trial with radiolabeled antibodies there was only 
a minor influence of these factors [38]. In 2000, Blumenthal and colleagues already reported 
that plasma levels of FLT3-L help to predict haematological toxicity after 
radioimmunotherapy [39]. In 2003 this was confirmed by Siegel et al. for 
radioimmunotherapy with iodinated anti-CEA antibodies [40]. However, no studies taking 
this into account are published for PRRT. Nevertheless, the importance of introducing 
biological parameters into treatment planning is indisputable [41].  
 
Promising results for predicting the haematological response were obtained by using ROI 
surrounding a section of the thoracic spine for determining the absorbed dose to the red 
marrow. In these studies the absorbed dose was calculated pretherapeutically with the positron 
emitter 86Y before treatment with [90Y-DOTA0-Tyr3]octreotide [22, 42]. Yttrium-86 can be 
regarded as the ideal surrogate for 90Y and offers a high resolution when using a PET-scanner. 
However, imaging with 86Y is currently only available in specialized centres because despite 
the need of a cyclotron to produce 86Y, the reconstruction of the PET data requires 
sophisticated correction algorithms. There is certain evidence in literature that imaging with 
86Y might overestimate doses, particularly if close to dense tissue as is  the spine [43, 44]. 
Besides, dosimetry using 86Y will be a gold standard only for treatments with 90Y because in 
PRRT the radionuclide used might influence the receptor affinity and consequently the 
biodistribution of the compound [45]. Moreover, the relatively short physical half life of 86Y 
(14.7 h) does not allow to follow the activity over several days which is important for the 
planning of the treatment with 177Lu. Despite these drawbacks of 86Y it should be emphasized 
that a very good dose response curve was found for predicting the haematological toxicity 
after [90Y-DOTA0,Tyr3]octreotide treatment [22, 42].  
 
So far one group found interesting results when calculating the absorbed radiation dose to the 
bone marrow from scans for radiolabeled antibodies using an integrated SPECT/CT camera 
[23]. The results are still lacking of confirmation by other groups and no results using this 
method with radiopeptides have been published so far. A validation of this method for 
radiopeptides is needed. Remarkably no bone marrow dosimetry was feasible on SPECT 
scans in our setting because none or only very faintly visible uptake in the bone marrow was 
present on the scans (Fig. 3). On the one hand this is an indication that the biodistribution is 
not identical for [86Y-DOTA0,Tyr3]octreotide and [177Lu-DOTA0,Tyr3]octreotate.  On the 
other hand this underlines the need of a different, reliable method for [177Lu-
DOTA0,Tyr3]octreotate dosimetry. The lower uptake in the bone marrow of radiopeptides 
compared to radiolabeled antibodies might be a drawback for this method in PRRT in general. 
Nevertheless it is an interesting method that should be evaluated further using a SPECT/CT.    
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We found a high correlation between the radioactivity in the blood and in the bone marrow 
aspirate during PRRT with [177Lu-DOTA0,Tyr3]octreotate. The most important explanation 
for the high congruence between the radioactivity measured in the blood and in the bone 
marrow aspirate is that the amount of stem cells in a bone marrow aspirate is low and that 
most of the aspirate consists of blood. On the other hand, the high volume of blood in the 
bone marrow aspiration reflects that the blood contributes most of the radiation absorbed dose 
to the bone marrow. Taking into consideration the path length of the common therapeutic 
radionuclides in the millimetre range and the structure of the bone marrow it is evident that 
the radiation from the blood will reach all bone marrow structures. Calculating the 
radioactivity in the remainder of the body on the other hand deals with the assumption of a 
homogeneous distribution of all the activity that is not excreted or absorbed in one of the 
source organs.  
 
As stated in the introduction, a homogenous distribution of the activity in the bone marrow 
has to be assumed in order to apply the blood-method for dosimetry. Again the high 
agreement between the radioactivity in the blood, where the activity is distributed 
homogeneously, and in the bone marrow aspirates indicates that this assumption might count 
in the case of small peptides. However, it is not possible to prove this assumption with these 
data.  
 
Measuring the radioactivity in the blood is simple, accurate and the discomfort for the patients 
is limited. Since the time radioactivity curve in blood usually is fitted by a bi-exponential or 
three exponential curve [17, 37], a sum of five blood samples appears to be reasonable [46] 
whereas the time points of drawing the blood should be chosen depending on the biokinetics 
of the vector and the half life of the radionuclide.  
 
The relation between the calculated absorbed doses to red marrow using different methods 
and the decrease in platelet counts is disappointing. A number of reasons may account for 
this. The absorbed doses were compared with only one post therapeutic platelet count. This 
platelet count, six weeks after the treatment, does not reflect the nadir of each patient. Another 
explanation could be the relatively small number of patients that was studied. Moreover, 
probably the most important reason is that the response of an individual patient to PRRT is 
not only related to the radiation absorbed dose in the bone marrow but also to the 
pretherapeutical status of the bone marrow. Especially previous, potentially haematocytotoxic 
treatments can influence the response after the treatment.  
 
At this point no conclusions can be drawn between the calculation of the radiation absorbed 
dose in the bone marrow and the risk of developing MDS. However, developing MDS is 
probably also related to the pretherapeutic status of the bone marrow and previous treatments. 
 
The field of bone marrow dosimetry is a large and very difficult field. Beside all factors 
mentioned previously that may influence the dosimetry of an individual patient, many other 
problems have to be faced. The bone marrow is not a solid organ and simply the 
determination of the mass is virtually impossible. As for all internal radiotherapy treatments 
the dose rate in PRRT is low. Most values that deal with the maximum tolerated dose of 
healthy organs are derived fom external beam radiation with a much higher dose rate. The 
influence of such physical properties is not well understood and may as well highly influence 
the results of internal dosimetry and the biological response.   
 
Calculating the absorbed dose to the bone marrow from both the blood and the remainder of 
the body appears to be a cautious, but feasible method.  Adding the radiation dose derived 
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from organs and tumours seems relatively insignificant. However, since the correlation with 
the drop in platelets is poor, more attention should be paid to other factors that might 
influence the haematological response after PRRT in the future. Also, because of the lack of 
correlation between any of the calculations for the bone marrow dose and the haematological 
response, no conclusions can be drawn from this study as to which theoretical model is 
adequate. Such testing of models requires dose escalation studies for which approval of 
medical ethical committees may prove impossible. 
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Abstract. Purpose: In vivo quantification of radiophar-
maceuticals has great potential as a tool in developing new
drugs. We investigated the accuracy of in vivo quantifica-
tion with multi-pinhole single-photon emission computed
tomography (SPECT) in rats.
Methods: Fifteen male Lewis rats with different stages
of renal dysfunction were injected with 50 MBq 99mTc-
dimercaptosuccinic acid. Four to six hours after injection,
SPECT of the kidneys was acquired with a new four-
headed multi-pinhole collimator camera. Immediately after
imaging the rats were sacrificed and the kidneys were
counted in a gamma-counter to determine the absorbed
activity. SPECT data were reconstructed iteratively and
regions of interest (ROIs) were drawn manually. The
absolute activity in the ROIs was determined.
Results: Uptake values ranging from 0.71% to 21.87% of
the injected activity were measured. A very strong linear
correlation was found between the determined activity in
vivo and ex vivo (r2=0.946; slope m=1.059).
Conclusion: Quantification in vivo using this multi-
pinhole SPECT system is highly accurate.
Keywords: Animal SPECT – In vivo quantification –
99mTc-DMSA – Renal uptake
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Introduction
In vivo quantification of radiopharmaceuticals has great
potential as a tool in the development of new drugs [1].
Accurate in vivo quantification allows the user to
determine the uptake of a radiopharmaceutical without
sacrificing the animal. Another consequence of accurate in
vivo quantification is that a physiological process can be
followed in the same animal over time.
Treatment with radiolabelled somatostatin analogues
has become the treatment of choice for patients with
metastatic, somatostatin receptor-positive neuroendocrine
tumours [2]. Such treatments, when repeated, result in a
high absorbed radiation dose in the kidney, which in turn
may cause renal failure [3]. To investigate the effect of
different agents on kidney protection during peptide
receptor radionuclide therapy (PRRT) in animals, a tool
to quantify the renal damage after PRRT is needed. Renal
damage after PRRT occurs mainly in the glomeruli and
proximal tubules of the kidneys [4]. 99mTc-dimercaptosuc-
cinic acid (DMSA) is a marker for tubular function [5].
After glomerular filtration, 99mTc-DMSA is taken up by
functional tubular cells. In this preliminary study we
investigated the accuracy of in vivo quantification of
99mTc-DMSA uptake in rat kidneys with the NanoSPECT,
a new multi-pinhole four-headed camera, after induction of
different levels of kidney damage by high-dose PRRT. In
several small-animal SPECT systems a very high resolu-
tion has been demonstrated previously [6, 7]. The
NanoSPECT is a small-animal SPECT system which has
been shown to greatly improve sensitivity while achieving
high, even submillimetre, resolution [8]. Some previous
studies have used semi-quantitative quantification methods
[9, 10], though to date only one small-animal SPECT study
has shown accuracy of absolute quantification in vivo. This
study, however, was performed with the Linoview system
using a different acquisition technique, and only two
animals were scanned [11]. Our aim was to investigate the
accuracy of in vivo quantification over a broad range of
activity concentrations in the animals.
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Materials and methods
The animal experiments were performed in compliance with the
regulations of the institution and with generally accepted guidelines
governing such work.
Radiopharmaceuticals
[177Lu-DOTA0,Tyr3]octreotate was synthesised and labelled as
described previously [12]. The 99mTc-DMSA kit was purchased
from GE Healthcare (Roosendaal, the Netherlands) and labelled
according to the indicated procedure.
Animal studies
Fifteen male Lewis rats were treated with different activities of
[177Lu-DOTA0,Tyr3]octreotate. The aim was to deliver renal irradi-
ation with different activities in order to induce different levels of
renal dysfunction. Two rats were not injected with the radiopeptide
and served as a control group. The activity injected in the other 13
rats ranged from 278 to 555 MBq.
Between 105 and 146 days after [177Lu-DOTA0,Tyr3]octreotate
injection, the rats received 50 MBq 99mTc-DMSA i.v., and 4–6 h after
99mTc-DMSA injection, SPECT was acquired as described below.
Immediately after the imaging procedure, the animals were
sacrificed, the left kidney was removed and the activity in the
kidney was determined in a gamma-counter (Perkin Elmer,
Groningen, the Netherlands). Beforehand the gamma-counter had
been calibrated with different volumes and activities to exclude
errors caused by volume effects or dead time.
Animal SPECT (NanoSPECT) and software
SPECT imaging was performed with a four-headed multiplexing
multi-pinhole NanoSPECT (Bioscan Inc., Washington D.C.) (Fig. 1).
Each head is fitted with an application-specific tungsten collimator
with nine pinholes. For this study we imaged with the rat apertures,
which comprise a total of 36 2-mm-diameter pinholes imaging a
cylindrical field of view that is 60 mm in diameter by 24 mm in
length. These rat apertures provide a reconstructed resolution below
1.6 mm at 140 keV, with an average sensitivity of 1,100 cps/MBq
across the field of view (FOV). The axial FOV is extended using a
step-and-shoot helical scan of the animal, with the user defining a
range from 24 to 270 mm according to the region to be imaged. The
energy peak for the camera was set at 140 keV. The window width
was ±10%. The rats were scanned 4–6 h after the injection of
approximately 50 MBq 99mTc-DMSA. An acquisition time of 30 s
per view was chosen, resulting in acquisition times ranging from 6 to
9 min per animal. After the acquisition, the data were reconstructed
iteratively with the HiSPECT (Bioscan Inc., Washington D.C., USA)
software, a dedicated ordered subsets-expectation maximisation
(OSEM) software package for multiplexing multi-pinhole recon-
struction. The NanoSPECT is calibrated with a phantom, approxi-
mately of the size of the animals, filled with a known activity of
99mTc such that voxel values in the reconstruction provide a proper
estimate of the activity level without further calculation. A region of
interest (ROI) was drawn manually around both kidneys; the 3D
activity distribution within the ROI was then summed to determine
the uptake. Because of the favourable biodistribution of 99mTc-
DMSA, limited to the kidneys, the ROI could be drawn generously to
prevent partial volume effects at the edges. No correction for scatter
was performed. All measured activities were corrected for decay and
expressed as % injected activity (%IA). The injected activity was
determined by measuring the syringe in a dose calibrator before and
after injection of the animal. The difference was defined as the
injected activity. Quantification of the ROI is performed with the
INTERVIEW XP (Mediso Ltd., Budapest, Hungary) software.
Statistical analyses
Linear regression was performed with the values calculated with
SPECT plotted against those collected with the gamma-counter. The
square of the correlation factor (r2) was then calculated to provide
some measure of the results.
Results
In all rats, both kidneys could be visualised. The spatial
resolution was very high. Differentiation between the
parenchyma characterised by tracer accumulation and the
cold regions indicative of the renal basin was easily
possible over a broad range of activity concentrations.
Scans of two animals with different activities in the kidneys
are demonstrated in Figs. 2 and 3. As a consequence of the
high contrast, the ROI around the kidney could be placed
indisputably.
Fig. 1. The NanoSPECT (Bioscan Inc., Washington D.C., USA), a
commercially available four-headed multiplexing multi-pinhole
camera
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Over the kidneys of the healthy animals with the highest
99mTc-DMSA uptake, we achieved count rates of approx.
1,500 cps per detector. The maximum capacity of the
detectors is specified by the manufacturer to be 50,000 cps.
Therefore effects of dead time can be excluded.
Uptake values of 0.71% to 20.77%IA were determined
in the gamma-counter. By comparison, SPECT values
ranging from 0.74 to 21.87%IA in the left kidney were
measured. We found a very good linear correlation between
the values determined by the gamma-counter and the
values determined by SPECT. The square of the correlation
factor was r2=0.946 and the slope of the correlation line
was m=1.059 (Fig. 4). Both qualitatively and quantita-
tively, the results showed strong agreement over a whole
range of activities.
The results determined by SPECT for the left and the
right kidney in the same animal were nearly identical. No
difference >1.5%IA was found (data not shown).
Discussion
We found a strong linear correlation between the two
methods determining the absolute activity of 99mTc-DMSA
in the kidney. The slope of the regression line and the
correlation factor were close to 1, indicating that the two
methods produce nearly identical results. We assumed the
determination in the gamma-counter to be the gold
standard, though both modalities used in this study have
some inherent variance. With these results, we have shown
that it is possible to perform absolute quantification of
activity in vivo with the NanoSPECT.
These results will influence our future planning of
animal studies. We have now demonstrated that this system
is capable of quantifying radiopharmaceuticals in vivo.
Thus, we can follow physiological processes in the same
animal over time, i.e., we are able to perform longitudinal
studies. In addition to saving animals, following a function
Fig. 2. Transaxial (a), coronal (b) and sagittal (c) slices of a rat
kidney acquired by multi-pinhole SPECT, 6 h after the injection of
50 MBq 99mTc-DMSA. Of note is the very high resolution. Clear
differentiation is possible between the parenchyma and the renal
basin. In the left kidney, 21.87%IA was determined by SPECT
Fig. 3. Transaxial (a), coronal (b) and sagittal (c) slices of a rat
kidney acquired by multi-pinhole SPECT. The experimental setting
and acquisition mode were as in Fig. 2. This rat had severe renal
damage after receiving 555 MBq [177Lu-DOTA0,Tyr3]octreotate
125 days earlier. In the left kidney, 3.08%IA was determined by
SPECT
1216
European Journal of Nuclear Medicine and Molecular Imaging Vol. 33, No. 10, October 2006
88 CHAPTER 4
in one animal over time is closer to the situation
encountered in clinical practice.
In our study we used 99mTc-DMSA, which is filtered by
the glomeruli and actively reabsorbed by the functional
tubule cells. This tracer is very suitable for quantification as
the activity is strictly limited to the organ of interest. The
volume of the ROI did not influence the results
substantially, since nearly no activity was located outside
the kidneys (data not shown). Further investigations will
have to show how reliable the results are when more
background activity is present, e.g. in tumours. When more
background activity is present, the shape and size of the
ROI will strongly influence the results, which in turn will
increase inter-observer variability. In the next generation of
the NanoSPECT, an X-ray CT will be implemented to
provide anatomical information that in turn will enable the
imager to better define ROIs.
We conclude that in our setting, in vivo quantification
with the NanoSPECT is highly accurate, resulting in
precise determination of the absolute activity in an ROI
over a broad range of activities of 99mTc-DMSA in rat
kidneys.
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ABSTRACT
In peptide receptor radionuclide therapy (PRRT), the dose-limiting organ is, most often, the kidney. How-
ever, the precise mechanism as well as the exact localization of kidney damage during PRRT have not
been fully elucidated. We studied renal damage in rats after therapy with different amounts of [177Lu-
DOTA0,Tyr3]octreotate and investigated 99mTc-DMSA (dimercaptosuccinic acid) as a tool to quantify re-
nal damage after PRRT. Experimental Design: Twenty-nine (29) rats were divided into 3 groups and in-
jected with either 0, 278, or 555 MBq [177Lu-DOTA0,Tyr3]octreotate, leading to approximately 0, 46, and
92 Gy to the renal cortex. More than 100 days after therapy, kidney damage was investigated using 99mTc-
DMSA single-photon emission computed tomography (SPECT) autoradiography, histology, and blood
analyses. Results: In vivo SPECT with 99mTc-DMSA resulted in high-resolution (1.6-mm) images. The
99mTc-DMSA uptake in the rat kidneys was inversely related with the earlier injected activity of [177Lu-
DOTA0,Tyr3]octreotate and correlated inversely with serum creatinine values. Renal ex vivo autoradi-
ograms showed a dose-dependent distribution pattern of 99mTc-DMSA. 99mTc-DMSA SPECT could dis-
tinguish between the rats that were injected with 278 or 555 MBq [177Lu-DOTA0,Tyr3]octreotate, whereas
histologic damage grading of the kidneys was nearly identical for these 2 groups. Histologic analyses in-
dicated that lower amounts of injected radioactivity caused damage mainly in the proximal tubules,
whereas as well the distal tubules were damaged after high-dose radioactivity. Conclusions: Renal dam-
age in rats after PRRT appeared to start in a dose-dependent manner in the proximal tubules and con-
tinued to the more distal tubules with increasing amounts of injected activity. In vivo SPECT measure-
ment of 99mTc-DMSA uptake was highly accurate to grade renal tubular damage after PRRT.
Key words: PRRT, renal damage, [177Lu-DOTA0,Tyr3]octreotate, 99mTc-DMSA, animal SPECT 
INTRODUCTION
Peptide receptor radionuclide therapy (PRRT)
with radiolabeled somatostatin analogs has be-
Address reprint requests to: Flavio Forrer; Department of
Nuclear Medicine, Erasmus MC Rotterdam; Dr. Molewa-
terplein 40, NL-3015 GD Rotterdam, The Netherlands;
Tel.: 0031-10-463-48-89; Fax: 0031-10-463-59-97
E-mail: fforrer@uhbs.ch
come an important tool in the management of
neuroendocrine tumors. Convincing results were
found for both objective tumor response and
quality of life.1–4 During PRRT, using somato-
statin analogs labeled with -emitters, such as
90Y and 177Lu, usually the kidney is the dose-lim-
iting organ.5,6
Although the major part of the radiopharma-
ceutical is excreted into the urine, the partial
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reabsorption in the tubular cells leads to a con-
siderable radiation dose to the radiosensitive kid-
neys.7,8 It was shown recently that the localiza-
tion of the radiopeptide in the kidney is not
homogeneous, but predominately in the cortex,
where it forms a striped pattern, with most of the
radioactivity centered in the inner cortical zone.9
In the only study that included biopsies of human
kidneys after PRRT, mainly thrombotic microan-
giopathy was found despite minor tubular atrophy
and interstitial fibrosis.10 In addition, it is known
that PRRT can lead to radiation nephritis.11,12 The
precise mechanism of renal damage, however, is
not fully known, nor has the localization of the
most pronounced damage yet been identified.
The potential coherence of the inhomogeneous
distribution of radioactivity in the kidney and the
localization of damage is highly relevant, as a
number of radionuclides potentially suitable for
therapy are available. The beta-emitters, 90Y,
177Lu, and 131I, are widely used for therapies with
a number of vectors.13,14 Several therapy studies
were performed with the Auger-emitter, 111In,
and several new radionuclides, including alpha-
emitters, are under investigation.15,16 The differ-
ent physical characteristics of these radionuclides
result in a different tissue penetration range of the
therapeutic particles and will, therefore, lead to a
different distribution pattern of absorbed radia-
tion dose in the kidney.17
The aim of this study was to investigate rat
kidneys more than 100 days after injections of
different amounts of [177Lu-DOTA0,Tyr3]oc-
treotate. The highest activity injected was in-
tended to induce severe kidney damage. The
kidneys were investigated with a number of
methods: in vivo autoradiography, histologic
analysis with different staining methods and
measurement of serum creatinine to get a com-
plete overview of function and morphology. As
it is known that radiopeptides are absorbed par-
tially in the tubular epithelial cells, in vivo sin-
gle-photon emission computed tomography
(SPECT) with 99mTc-DMSA (dimercaptosuc-
cinic acid) as a marker for renal tubular dam-
age,18,19 were acquired with a dedicated animal
SPECT camera (NanoSPECT Bioscan Inc.;
Washington, DC., USA), that allows absolute 
in vivo quantification of renal 99mTc-DMSA-
uptake.20 The 99mTc-DMSA scintigrams were
performed to evaluate the value of this tracer in
the follow-up of renal function after PRRT in
rats in order to develop a sensitive method to
follow renal function over time.
MATERIALS AND METHODS
Animal experiments were performed in compli-
ance with the regulations of the institution and
with generally accepted guidelines governing
such work.
Radiopharmaceuticals
[177Lu-DOTA0,Tyr3]octreotate was synthesized
and labeled as described previously.21 The 99mTc-
DMSA kit was purchased from GE Healthcare
(Buckinghamshire, United Kingdom) and labeled
according to the indicated procedure.
Animal Studies
Twenty-nine (29) young, male Lewis rats (Har-
lan; Horst, The Netherlands), with a body weight
of 250–300 g, were divided into 3 groups. The
control group consisted of 9 rats. Ten (10) rats
were intravenously (i.v.) injected with 278 MBq
[177Lu-DOTA0,Tyr3]octreotate and 10 rats with
555 MBq [177Lu-DOTA0,Tyr3]octreotate. In 20
rats (5 controls, 7 of the 278 MBq group and 8
of the 555 MBq group), SPECT scans with
99mTc-DMSA were acquired. Because renal dam-
age is late toxicity, the scans were acquired
between 109 and 146 days after the injection 
of 177Lu-DOTA0,Tyr3]octreotate. The 99mTc-
DMSA uptake in the kidneys was quantified, af-
ter which an autoradiogram of the 99mTc-DMSA
uptake was performed in 6 rats (2 from each
group). Kidneys from all animals were analyzed
histologically. 
Animal SPECT (NanoSPECT) and Software
SPECT imaging was performed with a four-
headed multiplexing multipinhole NanoSPECT.
Each head was outfitted with an application-spe-
cific tungsten collimator with 9 pinholes. For
this study, we imaged with rat apertures that
were comprised of a total of 36 2-mm diameter
pinholes imaging a cylindrical field of view that
was 60 mm in diameter by 24 mm in length.
These rat apertures provided a reconstructed
resolution below 1.6 mm at 140 keV, with an
average sensitivity of 1100 cps/MBq across the
field of view (FOV). The images were ac-
quired in a step-and-shoot helical scan-mode,
which allowed to image a defined range from
24 to 270 mm, according to the region to be im-
aged. The energy-peak for the camera was set
at 140 keV. The window width was 10%. The
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rats were scanned 4–6 hours after the injection
of 50 MBq 99mTc-DMSA. An acquisition time
of 30 seconds per projection was chosen, re-
sulting in total acquisition times ranging from 6
to 9 minutes per animal. The data were recon-
structed iteratively with the HiSPECT© software
(Bioscan), a dedicated ordered subsets-expecta-
tion maximisation (OSEM) software package
for multiplexing multipinhole reconstruction.
The NanoSPECT was calibrated with a phan-
tom, approximately of the size of the animals,
filled with a known activity of 99mTc, such that
voxel values in the reconstruction provided a
proper estimate of the activity level without fur-
ther calculation. 
A volume of interest (VOI) was drawn manu-
ally around both kidneys; the three-dimensional
(3D) activity distribution within the VOI was
then summed to determine the uptake. Because
of the favourable biodistribution of 99mTc-
DMSA, limited to the kidneys, the VOI could be
drawn generously to prevent partial-volume ef-
fects at the edges. All measured activities were
corrected for decay and expressed as percent in-
jected activity (%IA). The IA was determined by
measuring the syringe in a dose-calibrator before
and after injection of the animal. The difference
was defined as the IA. The quantification of the
VOI was performed with INTERVIEW XP© soft-
ware (Mediso Ltd.; Budapest, Hungary). After
imaging, the rats were sacrificed. 
Autoradiography
In 6 animals (2 from each group), after euthana-
sia, 1 kidney was removed, quickly frozen on liq-
uid nitrogen–cooled isopentane, and processed
further for autoradiography. The tissue was em-
bedded in TissueTek (Sakura; Zoeterwoude, The
Netherlands) and processed for cryosectioning, as
described previously.22 Briefly, tissue sections
(10-m) were mounted on glass slides. The sec-
tions were exposed to SR phosphor imaging
screens (Packard Instruments Co.; Canberra CT)
for 1 day in radiographic cassettes. The screens
were analyzed using a Cyclone phosphor imager
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Table 1. Criteria for the Histological Kidney Damage Score
Grade Overview Glomeruli Tubules
1 More or less normal Apoptotic cells in the Apoptotic cells
aspect endothelium Rough protein staining
High cell count Inflammatory infiltrate Little dilated
glomeruli Normal BM
No protein cylinders
2 Dilation of tubules Like grade 1 More apoptotic cells
Damaged tubule cells More pronounced 
dilation
BM thickened
Little protein cylinders
in tubules
Regenerating cells
(mitotic activity)
3 Stronger dilated tubules Vascular lumina Flat epithelium, partly
Cell-rich infiltrate smaller, few total loss of epithelium
Regenerating tubules erythrocytes Strong dilation
PAS: thickened BM Sometimes shrinkage Inflammatory infiltrate
PAS: protein cylinders Regeneration present
Protein cylinders
More pronounced BM
thickening
4 Heavily dilated tubules Like Grade 3 Like Grade 3, but more
Heavily thickened BM More optical empty empty cylinders
Protein cylinders space owing to shrinkage Periferal fibrosis
of glomeruli
BM, basal membrane
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and a computer-assisted OptiQuant 03.00 image
processing system (Packard).
Histology
Immediately after removing them from the ani-
mal, the kidneys were fixed in 10% neutral
buffered formalin, trimmed, and processed by
standard techniques for embedding in paraffin.
Four-micron (4-m) sections were cut and
stained with haematoxylin-eosin (HE) or periodic
acid-Schiff reagent (PAS). The microscopic re-
nal damage score (RDS) was graded, blinded to
the treatment protocol ranging from 0 (no dam-
age) to 4 (severe damage). The criteria for these
grades are listed in Table 1. The PAS-stained sec-
tions were used for better differentiation between
proximal and distal tubules.
Blood Analyses
At the day of sacrifice (134  11 days after in-
clusion), blood samples were drawn by cardiac
puncture from a total of 19 animals (6 controls,
6 of the 278 MBq group, and 7 of the 555 MBq
group). Blood chemistry and hematological pa-
rameters were determined by standard hospital
analysis procedures.
Statistics
To correlate the results, the Pearson’s correlation
coefficient was calculated. The Student’s t test
was used to test for significance of differences.
A p-value 0.05 was considered significant.
RESULTS
The administration of [177Lu-DOTA0,Tyr3]oc-
treotate to the rats was straightforward. No acute
discomfort was observed in the rats treated. Af-
ter inclusion, the body weight of the rats from all
the groups dropped slightly, by not more than 5%.
After this initial decline, the body weight of the
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Figure 1. Body weight [g] (mean standard deviation)
of the rats treated with 0 MBq [177Lu-DOTA0,Tyr3]octreo-
tate (A), with 278 MBq [177Lu-DOTA0,Tyr3]octreotate (B),
and with 555 MBq [177Lu-DOTA0,Tyr3]octreotate (C).
A B
C
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control group rats increased continuously, as ex-
pected. In contrast, the body weight of the rats
treated with 278 MBq initially increased slightly
and then remained stable, whereas the body
weight of the rats treated with 555 MBq initially
increased and then dropped approximately 70
days after PRRT (Fig. 1A–1C).
By SPECT with 99mTc-DMSA, in all rats, both
kidneys could be visualized, although kidneys in
the group injected with 555 MBq were only
faintly visible. The spatial resolution of the im-
ages was high, with a spatial resolution below 1.6
mm. Differentiation between functional paren-
chyma, characterized by tracer accumulation and
the cold regions indicative of the renal pelvis, was
easily determined (Fig. 2A–C). The renal uptake
of 99mTc-DMSA was significantly different be-
tween the 3 groups (all p  0.01). The mean val-
ues  standard deviation (SD) were 23.2 1.2
%IA for the control group, 9.9 6.3 %IA for the
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Figure 2. Coronal SPECT slices of rat kidneys acquired 4–6 hours after the injection of 50 MBq 99mTc-DMSA. The slices cor-
respond to the kidneys in Figures 3 and 4. (A) is from a control animal, (B) is from an animal 115 days after therapy with 278
MBq [177Lu-DOTA0,Tyr3]octreotate, and (C) is from an animal 109 days after therapy with 555 MBq [177Lu-DOTA0,Tyr3]oc-
treotate. SPECT, single-photon emission computed tomography; DMSA, dimercaptosuccinic acid.
A B C
Figure 3. Renal autoradiograms after an in vivo injection of 50 MBq 99mTc-DMSA. The rats were sacrificed 6 hours after in-
jection. (A) shows the autoradiogram of a control animal with a normal radioactivity distribution. (B) shows the autoradiogram
of an animal 115 days after therapy with 278 MBq [177Lu-DOTA0,Tyr3]octreotate. (C) shows the autoradiogram of an animal
109 days after therapy with 555 MBq [177Lu-DOTA0,Tyr3]octreotate. The images correspond to the kidneys in Figures 2 and 4.
DMSA, dimercaptosuccinic acid.
A B C
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Figure 4 (A–C). Low-power overviews (3) of coronal histologic slices of rat kidneys, stained with hematoxylin and eosin.
The slices correspond to Figures 2 and 3.
A B C
Figure 5. Histologic slices of the cortex and outer
medulla of rat kidneys, PAS stained, magnification 20.
(A) shows a normal histology from a control animal. (B)
is from an animal 115 days after therapy with 278 MBq
[177Lu-DOTA0,Tyr3]octreotate, showing a decrementa-
tion of tubular cells with necrotic epithelial cells, in-
flammatory infiltration, and intact distal tubules. (C) is
from an animal 109 days after therapy with 555 MBq
[177Lu-DOTA0,Tyr3]octreotate. Inflammatory infiltra-
tion, nearly complete decrementation of morphologically
normal tubular cells, and protein leakage to the tubular
volume can be seen.
A
C
B
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group injected with 278 MBq, and 1.4 0.5 %IA
for the group injected with 555 MBq.
Figure 3A–C shows examples of the auto-
radiograms with 99mTc-DMSA from rat kid-
neys after treatment with 0, 278, and 555 MBq
[177Lu-DOTA0,Tyr3]octreotate. Figure 3A shows
a normal distribution of 99mTc-DMSA in a
control rat, with a high accumulation in the 
renal cortex. In contrast, in Figure 3C, show-
ing an autoradiogram of a rat treated with 555
MBq [177Lu-DOTA0,Tyr3]octreotate, hardly any
99mTc-DMSA uptake can be seen, indicating a se-
verely damaged tubular function. Figure 3B
shows an autoradiogram of a rat treated with 278
MBq [177Lu-DOTA0,Tyr3]octreotate. Here, in-
termediate renal 99mTc-DMSA uptake was found.
The distribution pattern of the radioactivity was
obviously different, compared to that of the con-
trol rat. We found a “shift” of the radioactivity
from the cortex to the outer medulla. The corre-
sponding SPECT scans are displayed in Figure
2A–C. A very positive match between SPECT
and autoradiograms was found, underlining the
high accuracy of the SPECT images.
In the third row (Figure 4A–C), the corre-
sponding histologic HE-stained overview images
of adjacent slices of that providing the autoradi-
ograms are shown. A dose-dependent loss of
eosinophile cytoplasm can already be seen in the
low-power (3) overview.
The detailed histology showed, as expected, no
significant abnormalities in the control rats. One
(1) kidney was scored with a damage score of 2,
whereas all other kidneys did not show any dam-
age and were scored 0. An example of a histo-
logic, PAS-stained slice of a control rat is shown
in Figure 5A.
In the rats treated with 555 MBq, a detailed
histology revealed intense changes in the proxi-
mal and distal tubules [177Lu-DOTA0,Tyr3]oc-
treotate. A mixed picture with inhomogeneous
nuclei, apoptotic, and necrotic cells was found
(Figure 5C). In all kidneys of this group, we
found extensive protein leakage into the tubules
and collecting tubes. Furthermore, interstitial
nephritis with inflammation of the cells was
found. The glomeruli, however, showed no, or
only very mild, changes. Based on the criteria
given in Table 1, all kidneys of the rats treated
with 555 MBq were histologically scored as hav-
ing Grade 4 damage.
The rats treated with 278 MBq showed severe
histologic damage as well. The proximal tubules,
especially, were heavily damaged with atrophy,
dilatation, apoptotic nuclei, and necrosis. How-
ever, in contrast to the kidneys of the rats that
were treated with 555 MBq, there was a notable
number of tubules that did not show histologic
damage. The PAS staining revealed that these
were mainly distal tubules, located in the outer
medulla. In addition to the tubular damage, signs
of interstitial nephritis with inflammation of the
cells were found as well (Figure 5B). The tubu-
lar damage was accentuated in the cortex, which
reflects the uptake of 99mTc-DMSA very well.
The histologic scoring resulted in one Grade 2
score, one Grade 3 score, and eight Grade 4
scores. Thus, regarding only the histologic score,
no significant difference to the group treated with
555 MBq was found (p  0.18).
At the day of sacrifice, a blood sample was
drawn by cardiac puncture to measure the serum
creatinine values. The results (mean SD) were
36.5  17.5 mol/L in the control group,
129.7  79.9 mol/L in the group injected with
278 MBq, and 425.3 219.2 mol/L in the
group injected with 555 MBq. All differences be-
tween all groups were significant (p 0.05) (Fig.
6). Furthermore, a significant (p 0.01) correla-
tion was found between the creatinine values and
the %IA determined by SPECT.
DISCUSSION
High-dose PRRT could cause severe renal dam-
age in rats as well as in humans because of the
radiation-absorbed dose to the kidney during
46
Figure 6. Serum creatinine values [mol/L] (mean
standard deviation) of the 3 groups at the day of sacrifice.
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therapy.5,8,10,12 Recently, a number of new drugs
were introduced with the potential to reduce re-
nal toxicity during PRRT, but the effectiveness
of these drugs during PRRT remains to be proven
in patients.23–26 What is worthwhile to highlight
are the studies with amifostine, because this was
the first drug investigated for PRRT that did not
aim at reducing the renal uptake, but which acted
as a radical scavenger to systemically reduce the
toxic effects of the radiation. Because amifostine
acts by a completely different mechanism, a com-
bination with drugs that reduce the renal uptake
appears promising.23
To improve kidney protection during PRRT, it
is important to understand the mechanism of re-
nal damage. One step toward a better under-
standing could be close monitoring of kidney
function after PRRT in vivo and over time. The
newly available dedicated small-animal gamma
cameras offer the possibility to investigate phys-
iologic processes in the same animal over time.
However, a tracer, one that is easily available for
daily routine, needs to be defined. The relation
that was found between 99mTc-DMSA uptake and
serum creatinine values, as well as the relation
between 99mTc-DMSA uptake and the injected
activity of [177Lu-DOTA0,Tyr3]octreotate, indi-
cate that 99mTc-DMSA is an accurate marker for
renal function after PRRT in these animals.
The only work containing histologic data from
human kidneys after PRRT reports, despite minor
fibrosis and tubular atrophy, is mainly thrombotic
microangiopathy (involving glomeruli, arterioles,
and small arteries). These pathologic changes were
comparable to the changes found after external
beam radiation, when the kidney is within the field
of radiation. The data for this study were generated
by investigating kidney biopsies of patients after
treatment with DOTATOC labeled with 90Y, a
high-energy beta-emitter.10
Recently published data showed that the high-
est concentration of radiolabeled peptides in rat
and in human kidneys was found in the proximal
tubular cells.9,22 The multiligand scavenger re-
ceptor, megalin, appeared to play a crucial role
for the reabsorption of radiopeptides into the
tubular cells.27 Using the high-energy beta-emit-
ter 90Y, emitting beta particles with a maximum
energy of 2.27 MeV, will result in a fairly ho-
mogenous energy distribution over the whole kid-
ney, including a high radiation-absorbed dose to
the glomeruli.28 For this study 177Lu was used,
emitting beta particles with a maximum energy
of 0.50 MeV, which results in a significant lower-
tissue penetration range of these particles and a
different energy distribution over the kidney.
Taking into account the space between tubules
and glomeruli as well as microdosimetric aspects,
a lower radiation-absorbed dose to the glomeruli
when using 177Lu, compared to 90Y, can be ex-
pected. It was calculated recently that other radi-
olanthanides with even lower energy beta parti-
cles could improve energy distribution further.16
Recently, several articles were published using
alpha-emitters for internal radiation therapy.28–30
After the administration of 213Bi-labeled DOTA-
TOC to Lewis rats, no histologic changes were
observed in kidney glomeruli and tubules. As a
consequence of the treatment with 22.2 MBq of
213Bi-DOTATOC, a merely mild interstitial
nephritis was observed. It is very likely that the
physical characteristics of the radionuclide that
was used might have had a strong influence on
kidney damage and might be one of the reasons
why no histologic changes in the glomeruli were
found in this study using 177Lu.
The estimated radiation-absorbed dose to the
kidney is high after a single-dose administration of
278 or 555 MBq [177Lu-DOTA0,Tyr3]octreotate in
rats. Dosimetric calculations showed that injecting
these activities into rats resulted in doses to the cor-
tex of approximately 46 and 92 Gy, respectively,
and approximately 35 and 70 Gy, respectively, to
the whole kidney.17 For the treatment of patients,
a maximum tolerated dose to the kidneys of 23 Gy
is generally accepted, although this value is derived
from external beam radiation, dealing with differ-
ent properties, especially concerning the dose rate
and energy distribution within the kidney.6 Taking
into account the potential dose reduction by the
coinfusion of amino acids, 278 MBq of [177Lu-
DOTA0,Tyr3]octreotate would result in approxi-
mately 23 Gy. 
The results of this rat study strongly suggest
that late renal damage after high-dose [177Lu-
DOTA0,Tyr3]octreotate therapy is mainly tubu-
lar. This is supported by the results of the 99mTc-
DMSA studies, being a marker for the renal
tubular function. The dose-dependent reduction
of 99mTc-DMSA uptake in the rat tubules sug-
gests that [177Lu-DOTA0,Tyr3]octreotate pro-
vokes a dose-dependent tubular damage.
CONCLUSIONS
In conclusion, 99mTc-DMSA appears to be a good
marker to quantify the extent of damage after
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PRRT. Using 99mTc-DMSA in combination with
a dedicated small-animal gamma camera will al-
low for the following of renal function after
PRRT in animals over time.
The localization and extent of damage, respec-
tively, after PRRT was found to be dose depen-
dent. Whereas in rats treated with 278 MBq
[177Lu-DOTA0,Tyr3]octreotate kidney damage
was found to be mainly in the proximal tubule,
higher injected radioactivities resulted in a de-
cline of morphologically undamaged tubules.
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Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues was 
proven to be a well tolerated, effective treatment for patients with metastatic, somatostatin 
receptor positive neuroendocrine tumors [1-8]. An overview of the current status as well as 
some perspectives is given in chapter 1. In chapter 2a a clinical study including 116 patients 
treated with 90Y-DOTATOC demonstrates exemplary the effectiveness as well as potential 
toxicity of PRRT with 90Y-DOTATOC. In general, the treatment is well tolerated and side-
effects are mostly rare and transient. The kidney is the dose-limiting organ in most studies, 
especially in all studies with 90Y labeled somatostatin analogs. Recently the bone marrow was 
identified as the dose limiting organ in 70% of the patients that are treated with 177Lu-
DOTATATE (personal communication, D.J. Kwekkeboom). Although PRRT with 
radiolabeled somatostatin analogues can be regarded as the treatment of choice for patients 
with metastatic, somatostatin receptor positive neuroendocrine tumors most of the patients 
relapse after a certain time. For this situation we demonstrated that re-treatment is feasible and 
effective with tolerable toxicity in the case of relapse [9]. This is shown in a clinical study in 
chapter 2b. Interestingly a good response after the first treatment was identified as a positive 
predictive factor for a good response after the second treatment. Although the effectiveness of 
PRRT was proven with regard to tumor load, quality of life as well as overall survival, certain 
limitations still arise. For example it remains unclear which somatostatin analogue is most 
suitable for treatment. In chapter 3a five patients with somatostatin receptor positive tumors 
were studied with two different peptides. Three out of these five showed a better tumor-to-
kidney-ratio with 111In-DOTATOC whereas one showed a better tumor-to-kidney-ratio with 
111In-DOTATATE. Somewhat different results were found by Esser and colleagues who 
compared 177Lu-DOTATOC with 177Lu-DOTATATE [10]. In this study only one out of 7 
patients had a more favorable tumor-to-kidney-ratio with DOTATOC. Beside other possible 
explanations, one reason for these differences might be that neuroendocrine tumors are a 
highly heterogeneous group of malignancies, showing different profiles of receptor 
expression. The slightly diverse affinity profiles of DOTATOC and DOTATATE might, 
depending on the receptor expression on the tumor, result in different tumor-to-kidney-ratios.  
 
Currently a vast number of different somatostatin analogs with different affinity profiles are 
available [11]. Individualized treatment planning with patient specific dosimetry might help to 
improve PRRT. Currently this is not feasible since the time and effort needed for one patient 
are vastly to big. In addition, many difficulties have to be overcome in internal dosimetry. 
Some of the difficulties as well as possible solutions are shown in chapter 3b exemplary for 
bone marrow dosimetry. It is obvious that currently no fully accurate dosimetry can be 
performed. Using diverse methods, huge differences in the calculated absorbed doses were 
found [12]. Additionally, a number of other factors, like e.g. the dose rate which a lot lower in 
nuclear medicine therapies compared to external beam radiation, are not fully understood and 
might influence the effects of the radiation treatment. Another role of dosimetry could be to 
predict the hematological response after PRRT. However, no correlation was found between 
the calculated absorbed dose to the red marrow and the drop in platelets after therapy. It 
seems are that e.g. the influence of factors like cytokines or pre-treatments with other 
potentially toxic drugs are important, but not many studies in this field have been performed 
as yet. More studies are needed to improve internal dosimetry further in order to achieve more 
reliable results and to be able to predict benefit and toxicity more precisely. Nevertheless, 
dosimetry, in particular pre-therapeutic dosimetry would be desirable to improve PRRT as 
well as to improve the understanding of physiological processes after PRRT.  
Especially with regard to radiation-biological processes animal studies can help to improve 
the understanding. In chapter 4a we showed that it is possible to determine accurately in vivo 
the absolute radioactivity with a dedicated small animal SPECT camera. This will allow to 
104 CHAPTER 5
perform accurate in vivo dosimetry and to follow the same animal to study the corresponding 
late toxicity [13].  
In general, true in vivo investigations enabled by small animal imaging allows following one 
animal over time and to study different functions over time. This appears to be of particular 
interest in therapy studies since side effects are often late toxicity whereas e.g. dosimtery has 
to be performed during therapy. By investigating the same animal a bias between the different 
groups can be excluded. In addition, small animal imaging will help to reduce the number of 
animals that is needed to answer a particular question. In the long turn this will safe costs – 
notably when genetically engineered animals are used - as well as it will reduce disputes from 
an ethical point of view.  
Currently, mainly the absorbed radiation dose to the kidneys is the dose limiting factor for 
PRRT with radiolabeled somatostatin analogues [1]. Co-infusion of cationic amino acids 
became a standard procedure during PRRT since it was shown that an amino acid co-infusion 
can reduce the kidney uptake by up to 50 % [14]. Lately, several new strategies to decrease 
renal toxicity further have been developed [15-17]. It remains unclear whether these new 
methods will replace the amino acid co-infusion or if they can be applied together with an 
amino-acid co-infusion in order to achieve an additional effect.  
To improve the kidney protection further it is important to understand the mechanism of 
damage during PRRT better. In chapter 4b the localization of the damage was analyzed with 
different methods: In vivo 99mTc-DMSA SPECT, histology with different staining, and 
biochemical analyzes. A clear dose dependency of the damage could be demonstrated. 
Additionally we found indications that the damage starts in the proximal tubules when lower 
amounts of radioactivity are applied. During high dose treatments the damage appears to be 
more extensive, involving the distal tubules as well. Furthermore we could prove that 99mTc-
DMSA is a highly valuable tracer to grade renal damage after PRRT in rats. E.g. we found a 
very good correlation between the 99mTc-DMSA-uptake and the 1/creatinine value. This 
finding of 99mTc-DMSA being a valuable tracer to quantify kidney damage after PRRT will 
have impact on further preclinical studies on kidney protection during PRRT. With all the 
studies we performed in rats with 99mTc-DMSA, we established rough normal values for 
99mTc-DMSA in rats. In the future it will be possible to compare kidney function 
quantitatively in different rats and longitudinally or even in rats from different studies. 
It will be interesting to investigate whether 99mTc-DMSA could be a valuable tracer in patients 
too. In comparison to patients [18] we did not find any glomerular damage in rats. However, 
since the patient study was performed with 90Y and the rat study with 177Lu the question arises 
if physical characteristics of the radionuclide might be responsible for the different 
localization of the damage. Recent studies in micro-dosimetry revealed significant differences 
in the dose distribution when different radionuclides were used [19]. It appears that the most 
suitable radionuclide for PRRT is not defined as yet.  
 
 
Conclusions 
 
Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is the 
treatment of choice for patients with metastatic, neuroendocrine, somatostatin receptor 
positive tumors. The treatment is generally well tolerated and the toxicity is low. Re-treatment 
after a standard therapy is feasible; however, the dose limiting organ is usually the kidney that 
will make further therapies impossible at some point. Many different somatostatin analogues 
with somewhat diverse affinity profiles for the somatostatin receptor subtypes are available. 
The most suitable peptide for PRRT in neuroendocrine tumors still remains to be defined. It 
appears that in different patients different peptides might have more favorable characteristics. 
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Unfortunately, accurate dosimetry is difficult and an individual, pre-therapeutic dosimetry 
with different peptides is currently not feasible.  
Many new approaches are currently investigated with the goal to improve PRRT, e.g. new 
agents to protect the kidneys or new peptides with improved characteristics. Newly 
developed, dedicated small animal SPECT/CT cameras with sub-millimeter resolution allow 
performing real in vivo studies on a pre-clinical level. This will help to design studies in a 
setting that is much closer to the situation as it is given in patients. The possibility to reliably 
quantify activity in vivo gives the opportunity to follow an animal over time and to investigate 
different physiological functions in the same animal. Among other methods the small animal 
SPECT/CT helped to localize the damage in the kidney after high dose PRRT more precisely. 
This might have consequences for the design of new peptides as well as for the planning of 
further studies.    
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Peptide-receptor-radionuclidentherapie (PRRT) met radioactief gelabelde somatostatine 
analoga heeft bewezen een goed te verdragen, effectieve behandeling te zijn voor patiënten 
met gemetastaseerde somatostatinereceptor-positieve neuroendocriene tumoren [1-8]. Een 
overzicht van de huidige status alsmede enige toekomstperspectieven worden weergegeven in 
hoofdstuk 1. In hoofdstuk 2a wordt een klinische studie beschreven van 116 met 90Y-
DOTATOC behandelde patiënten die duidelijk zowel de effectiviteit als ook de mogelijke 
toxiciteit van PRRT met 90Y-DOTATOC weergeeft. De behandeling is in het algemeen goed 
te verdragen en bijwerkingen zijn zeldzaam en van voorbijgaande aard. In de meeste studies is 
de nier het orgaan dat de dosislimiet bepaalt, met name in alle studies met 90Y gelabelde 
somatostatine analoga. Recent is vastgesteld dat bij 70% van met 177Lu-DOTATATE 
behandelde patiënten het beenmerg mede de dosislimiet bepaalde (persoonlijke mededeling 
van D.J. Kwekkeboom). Hoewel PRRT met radiogelabelde somatostatine analoga gezien 
wordt als voorkeursbehandeling voor patiënten met gemetastaseerde somatostatinereceptor-
positieve neuroendocriene tumoren, krijgen de meeste patiënten na zekere tijd een terugval 
vanwege groei van de tumor(en). Voor dergelijke patienten  geval tooonden wij aan dat een 
voortgaande behandeling mogelijk en effectief is met een toelaatbare toxiciteit [9]. Dit wordt 
aangetoond in een klinische studie beschreven in hoofdstuk 2b. Van belang is dat een goede 
reactie op de eerste behandeling gezien kan worden als een positief voorspellende factor voor 
een goede reactie na een tweede behandeling. Hoewel de effecten van PRRT gunstig zijn met 
betrekking tot tumorregressie, kwaliteit van leven en overleving, blijven er nog zekere 
beperkingen over. Het blijft bijvoorbeeld onduidelijk welk somatostatine analoog het meest 
geschikt is voor behandeling. In hoofdstuk 3a wordt de behandeling met twee verschillende 
peptiden bij vijf patiënten beschreven. In drie van deze vijf patiënten blijkt een betere 
tumor/nier ratio gevonden te worden met 111In-DOTATOC terwijl 111In-DOTATATE in één 
patiënt een betere tumor/nier ratio geeft . Iets andere resultaten werden gevonden door Esser 
en collega’s die 177Lu-DOTATOC met 177Lu-DOTATATE vergeleken [10]. In deze studie gaf 
DOTATOC maar in één van de zeven patiënten een betere tumor/nier ratio. Deze verschillen 
kunnen veroorzaakt zijn door het feit dat neuroendocriene tumoren behoren tot een in hoge 
mate heterogene groep maligniteiten met verschillende profielen van receptorexpressie. De 
enigszins verschillende affiniteitsprofielen van DOTATOC en DOTATATE kunnen, 
afhankelijk van de receptorexpressie van de tumor, verschillen in tumor/nier ratio opleveren.  
 
Op dit moment is er een groot aantal verschillende somatostatine analoga met onderscheidend 
affiniteitsprofiel beschikbaar [11]. Een op het individu gericht behandelplan met een 
patiëntgerichte dosimetrie kan helpen de PRRT te verbeteren. Momenteel is dit nog niet 
haalbaar vanwege de te investeren tijd per patiënt, bovendien moeten nog veel problemen bij 
het bepalen van de interne dosimetrie overwonnen worden. Sommige problemen alsmede 
mogelijke oplossingen typisch voor beenmergdosimetrie worden in hoofdstuk 3b beschreven. 
Het is onmiskenbaar dat op dit moment geen volledig nauwkeurige dosimetrie gedaan kan 
worden. Bij de verschillende gebruikte methoden zijn er grote verschillen in de berekende 
geabsorbeerde doses gevonden [12]. Bovendien is een aantal andere factoren die de effecten 
van een bestralingsbehandeling kunnen beinvloeden, zoals bijvoorbeeld  het dosistempo van 
de ioniserende straling die bij therapieën in de nucleaire geneeskunde een stuk lager is dan bij 
uitwendige bestraling, niet volledig bekend. Een andere rol voor dosimetrie ligt in de 
voorspelling van de hematologische reactie na PRRT. Er is echter geen correlatie gevonden 
tussen de berekende geabsorbeerde dosis en de achteruitgang in trombocytenaantal na 
therapie. Het lijkt dat de invloed van bijvoorbeeld cytokines en voorbehandeling met andere 
beschikbare chemotherapeutica van belang zijn, maar er zijn nog niet veel studies gedaan op 
dit gebied. Er zijn meer studies nodig om goed gebruik te kunnen maken van interne 
dosimetrie teneinde meer betrouwbare resultaten te verkrijgen waardoor we in staat zijn om 
de voordelen en toxiciteit nauwkeuriger te voorspellen. Niettemin, dosimetrie, in het 
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bijzonder pre-therapeutische dosimetrie, zou een welkome aanvulling zijn om PRRT te 
verbeteren alsmede om meer inzicht te verkrijgen in het fysiologische proces na PRRT.  
Speciaal met betrekking tot de stralingsbiologische processen kan onderzoek met proefdieren 
helpen om de inzichten te vergroten. In hoofdstuk 4a laten we zien dat het in vivo mogelijk is 
om zeer nauwkeurig de absolute hoeveelheid radioactiviteit vast te stellen met behulp van een 
specifieke SPECT camera, voor kleine dieren. Deze zorgt er voor dat in een dier nauwkeurig 
de in vivo dosimetrie bepaald kan worden en dat tevens hetzelfde dier gevolgd kan worden 
voor het vastleggen van toxiciteit na verloop van tijd [13].  
In het algemeen worden waardevolle in vivo onderzoeken verkregen met “small animal 
imaging” door het volgen van een enkel dier en de verschillende functies in de tijd te 
bestuderen. Dit blijkt van bijzonder belang te zijn bij therapiestudies, omdat neveneffecten 
vaak op langere termijn toxiciteit opleveren. Dit betekent dat bijvoorbeeld dosimetrie bepaald 
moet worden tijdens de therapie. Door hetzelfde dier te onderzoeken kan een afwijking tussen 
de verschillende groepen worden uitgesloten.  Daarbij zal de “small animal imaging” het 
aantal dieren, dat nodig is om een antwoord te verkrijgen op een specifieke vraag, helpen 
verminderen. Uiteindelijk zal dit kostenbesparend werken - met name wanneer er genetisch 
gemodificeerde dieren worden gebruikt - en ook zal het de discussies vanuit een ethisch 
standpunt beperken.  
Op dit moment is hoofdzakelijk de geabsorbeerde stralingsdosis in de nieren de beperkende 
factor bij PRRT met radioactief gelabelde somatostatine analoga [1]. Een infuus met 
aminozuren is een standaardprocedure bij PRRT, omdat is aangetoond dat een gelijktijdig 
gegeven infuus met aminozuren de opname in de nieren met 50% kan reduceren [14]. 
Onlangs zijn er verscheidene nieuwe strategieën ontwikkeld om de toxiciteit in de nier te 
verminderen [15-17]. Het lijkt nog onduidelijk welke van deze nieuwe methoden de plaats zal 
innemen van het aminozuurinfuus of dat ze samen toegediend kunnen worden om een 
aanvullend effect te verkrijgen.  
Om de nierbescherming verder te verbeteren is het belangrijk om het mechanisme van de 
schade door PRRT beter te begrijpen. In hoofdstuk 4b  is de locatie van de schade 
geanalyseerd met verschillende methoden: in vivo 99mTc-DMSA SPECT, histologie met 
verschillende kleuringen en biochemische analyses. Een duidelijke dosisafhankelijkheid van 
de schade kon worden vastgesteld. Daarbij vonden we aanwijzingen dat de schade in de 
proximale tubuli al begint wanneer lagere hoeveelheden radioactiviteit worden toegediend. 
Schade bij behandelingen met hoge doses blijkt meer intensief te zijn; ook de distale tubuli 
lopen dan schade op. Verder konden we bewijzen dat 99mTc-DMSA een zeer waardevolle 
tracer is om de graad van nierschade in ratten te bepalen na PRRT. We vonden bijvoorbeeld 
ook een erg goede correlatie tussen de 99mTc-DMSA-opname en de 1/creatinine waarde. Deze 
bevinding van 99mTc-DMSA als een waardevolle tracer om nierschade te kwantificeren na 
PRRT, zal van betekenis zijn voor verdere preklinische studies op het gebied van 
nierbescherming tijdens PRRT. Met alle studies die we met 99mTc-DMSA in ratten hebben 
gedaan, hebben we grofweg de normale waarden voor 99mTc-DMSA nieropname in ratten 
vastgesteld. In de toekomst zal het mogelijk zijn om de nierfunctie kwantitatief in 
verschillende ratten te vergelijken of zelfs in ratten uit verschillende studies. 
Het zal interessant zijn om te onderzoeken of 99mTc-DMSA ook een waardevolle tracer is 
voor patiënten. In vergelijking met patiënten [18] vonden we geen glomerulaire schade in 
ratten. Omdat de patiëntenstudie is uitgevoerd met 90Y en de rattenstudie met 177Lu doet zich 
echter de vraag voor of fysische eigenschappen van het radionuclide verantwoordelijk kunnen 
zijn voor de verschillen in locatie van de schade. Recente onderzoeken in micro-dosimetrie 
wezen uit dat er significante verschillen zijn in dosisverdeling wanneer er verschillende 
radionucliden worden gebruikt [19]. Het blijkt dat het meest geschikte radionuclide voor 
PRRT nog niet is gedefinieerd.  
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Conclusies 
 
Peptide receptor radionuclide therapie (PRRT) met radioactief gelabelde somatostatine 
analoga is de voorkeursbehandeling voor patiënten met gemetastaseerde neuroendocriene 
somatostatinereceptor-positieve tumoren. De behandeling is in het algemeen goed te 
verdragen en de toxiciteit is laag. Opnieuw behandelen na de standaardtherapie is mogelijk; 
echter het orgaan dat de dosislimiet bepaalt, meestal de nier, maakt verdere therapie op een 
gegeven moment onmogelijk. Veel verschillende somatostatine analoga met enigszins diverse 
affiniteitsprofielen voor somatostatine-receptorsubtypen zijn beschikbaar. Welk peptide het 
meest geschikt is voor PRRT bij neuroendocriene tumoren moet nog verder bepaald worden. 
Het blijkt dat bij verschillende patiënten verschillende peptiden meer of minder gunstige 
eigenschappen kunnen hebben. Jammer genoeg is nauwkeurige dosimetrie moeilijk en een 
individuele dosimetrie voor therapiebehandeling met verschillende peptiden op dit moment 
niet mogelijk.  
Vele nieuwe manieren van aanpak worden op dit moment onderzocht met als doel de PRRT te 
verbeteren, bijvoorbeeld nieuwe middelen om de nieren te beschermen of nieuwe peptiden 
met verbeterde eigenschappen. Een recente ontwikkeling is het gebruik van de “kleine dieren” 
SPECT/CT camera’s met submillimeterresolutie die de mogelijkheid geven echt in vivo 
studies op preklinisch niveau te doen. Dit zal helpen om onderzoek op te zetten in een situatie 
die veel meer op die van patiënten lijkt. De mogelijkheid om de radioactiviteit in vivo 
betrouwbaar te kwantificeren geeft de gelegenheid om een dier te volgen in de tijd en de 
verschillende fysiologische functies in hetzelfde dier te onderzoeken. Tezamen met andere 
methoden hielp de small animal SPECT/CT om de schade in de nier nauwkeuriger te 
lokaliseren na een hoge dosis PRRT. Dit gegeven kan gevolgen hebben voor zowel het 
ontwerpen van nieuwe peptiden als voor de planning van verdere onderzoeken.    
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